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ABSTRACT 
 
MEDICATION COST AND UTILIZATION IN HOSPICE CARE: 
AN ANALYSIS OF 2007 CLAIMS DATA 
 
 
 
By 
Rachi H. Parekh 
May 2013 
 
Thesis Supervised by Dr. Khalid M. Kamal 
Objectives: 
1. Describe patient-related and hospice-related characteristics such as gender, 
average length of hospice stay, primary diagnoses, average daily census, number 
of admissions per year, net operating revenues, inpatient unit (IPU) operating 
costs, and medication expenditures of hospices in Ohio and compare it with 
NHPCO data. 
 
2. Identify and analyze therapeutic drug classes and medications with the most 
frequent utilization rates and largest percentage of expenditures in hospice care. 
 
v 
 
Method: 
Hospice Pharmacy Benefit Managers (PBM) employ pharmacists to provide 
comprehensive pharmaceutical care services for patients under hospice care and one 
component of pharmacist provided services include comprehensive medication review. 
To study the impact of pharmacist-led medication review on hospice costs and 
medication utilization, PBM claims data for year 2007 were obtained from five hospices 
in Ohio. The data included information on utilization and costs of medications, patient-
related (gender, average length of hospice service, and primary diagnoses) and hospice-
related (number of admissions per year, average daily census, net operating revenues, 
inpatient unit [IPU] operating costs and pharmacy costs) characteristics. Claims data were 
analyzed to identify the most frequently used therapeutic drug classes and those classes 
which contributed to the largest percentage of pharmacy expenditures. Prescription drug 
count and total cost for medications under the identified therapeutic drug classes were 
also obtained. For benchmarking purposes, analysis was conducted to compare patient 
and hospice-related data obtained from the five hospices to the 2007 NHPCO data. 
 
Results: 
The average number of admissions per hospice for the year 2007 was 627 
patients. Average daily census (136 patients) and total patient days (51,350 days) in these 
five hospices were 1.5 times higher as compared to that of NHPCO data (90 patients and 
31,300 days, respectively.). Annual drug expenditures per hospice ranged from $67,580 
to $763,413 while average hospice medication cost per patient per day (PPPD) was 
$11.12 ($12.43 PPPD for home care and $8.5 PPPD for nursing care).  Average PPPD 
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excluding outliers such as enoxaparin was $10.72 ($12.05 PPPD for home care and $8.25 
PPPD for nursing care). 
 
Approximately 1,020 different drugs under 246 therapeutic classes were utilized 
in the five hospices. The most frequently utilized therapeutic class of drugs, based on 
prescription drug volume included analgesic-narcotics (15.6%) followed by laxatives-
cathartics (7.5%), and anti-anxiety drugs (7%). Therapeutic classes contributing to the 
majority of drug expenditures, included analgesics-narcotics (16.5%), SSRIs (4.7%), and 
anti-anxiety drugs (4.5%). Medications whose frequency of use accounted for high 
expense included morphine sulfate (5.3% - utilization, 4.4% - expenditure), lorazepam 
(4.4%, 3.1%), furosemide (4%, 0.6%), methadone (3%, 0.9%), and prednisone (3.1%, 
0.5%). Medications such as enoxaparin injections whose frequency of utilization was low 
(0.01%), contributed to 3.1% of total medication expenditure. Likewise, fentanyl and 
oxycodone contributed to 3.5% and 3.7%, respectively to the total medication 
expenditure, but their frequency of utilization was only 0.9% and 1.9%, respectively. 
 
Conclusion: 
The five hospices in Ohio utilized preferred drugs recommended by pharmacists 
following a medication review to identify potential drug related problems (DRPs) and 
encourage cost-effective drug utilization. As a result of these interventions, the utilization 
of expensive medications is low. Pharmacists specializing in hospice and palliative care 
are able to recommend preferred medications in end-of-life care thus producing cost-
savings.  More importantly, hospice pharmacists frequently identify DRP’s which can 
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improve patient outcomes. Hospices should consider interventions made by pharmacists 
and place emphasis on the utilization of cost effective drugs that can be used among 
terminally ill patients to provide a high level of quality care with fiscal responsibility. 
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CHAPTER 1 
INTRODUCTION 
 
The hospice regulations authorizing Medicare reimbursement for hospice-care 
services was issued in 1983 and updated in 2008. Beginning in 1984, there have been 
significant increases in both the number of programs offering hospice care and the 
number of patients who have received hospice care, especially during the past decade. 
According to the National Hospice and Palliative Care Organization (NHPCO), the 
number of patients who received hospice care in United States (US) increased from 
25,000 in 1982 to 100,000 patients’ in1984.1 In 2006, more than 1.3 million patients 
received hospice care from more than 4,500 hospice programs nationwide. 1, 2 
Furthermore, pediatric hospice programs have also grown as a result of community need. 
Pediatric patients account for approximately 1% of the hospice patients’ served.3 
 
Hospice programs are defined as a program of palliative and supportive care 
services providing physical, psychological, social, and spiritual care for terminally ill 
persons, their families, and caregivers. 4 Many patients receiving end-stage disease 
treatments which have little beneficial effects (e.g., chemotherapy, tube feedings, 
parenteral nutrition), require skilled help in transitioning to more useful forms of 
supportive care, such as hospice care. 5 The treatment focus is palliative, not curative, and 
is based on a biopsychosocial model rather than a disease model of care. 6 Palliative care 
is treatment for relief of pain and other uncomfortable symptoms through the appropriate 
coordination of all aspects of care to maximize personal comfort and relieve distress. 7 
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Palliative care can be provided outside of a hospice program, however hospice care is 
always considered to be palliative care. Hospice care allows the patient to remain at home 
for as long as possible by providing support to the patient and family, and keeping the 
patient as comfortable as possible while maintaining the patient’s dignity and quality of 
life. 
 
Hospice programs render services to both the patient and the family and consider 
them as one unit of care. Most hospice care services are provided in home or in inpatient 
settings (e.g., hospital, freestanding hospice facility, nursing home). Hospice services 
may be provided to patients in all age groups, including children, adults and the elderly. 4 
Hospice programs generally include services such as nursing care, physician services, 
nurse practitioner services, medical social services, and supportive services in the 
patient’s home or in an in-patient environment.  Typically, inpatient care is short-term, 
and is provided for control of pain and management of acute symptoms (e.g., intractable 
nausea, vomiting, seizures), or to provide respite care for relief of the patient’s primary 
caregivers. Short-term inpatient hospice care may also be provided in order to prepare the 
patient and family for home-care services. 8 
 
Under current Medicare guidelines, a hospice care program is considered to be a 
coordinated, interdisciplinary program and generally includes services provided by a 
physician, psychologist, social worker, nurses, dieticians, pharmacists, rehabilitation 
therapists, including speech, occupational and physical therapists, clergy, and home 
health services. Medicare certified hospice programs provide care using a team of people 
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who assess the needs of the patient and the family and then develop and maintain a plan 
of care that meets those needs. Once a patient is admitted to an approved hospice 
program, the hospice provider coordinates all care related to the management of the 
patient’s terminal illness. 4 Currently, more than 90% of the hospice programs in the 
United States are certified by Medicare. 6 
 
Determining the Need for Hospice Services 
 The decision to elect hospice care services remains a difficult choice. A common 
obstacle to timely referral for hospice services is often the physician’s perception that the 
patient and the family are not ready to consider hospice. In addition, predicting the time 
of death is difficult and often uncertain.11 Some prognostic indicators of limited life 
expectancy are disease-specific while some are not. End-stage diseases such as cancer, 
heart failure, pulmonary disease, dementia, and stroke are chronic conditions that 
physicians frequently encounter and may require hospice referral. Other illnesses, less 
frequently encountered by physicians, which may result in a hospice referral, include 
AIDS, liver failure, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease 
and amyotrophic lateral sclerosis (ALS).9                               
 
 In some cases, there may not be a single disease process that limits life 
expectancy. General guidelines published by NHPCO, previously referred to as the 
National Hospice Organization [NHO], 1996), 9 may be used to help determine hospice 
eligibility in selected non-cancer diseases. The guidelines do not predict prognosis; 
however, they have been adapted by regulators as standards for hospice eligibility.10 
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Other assessment tools used to determine prognosis and hospice eligibility include the 
Functional Assessment Staging Scale (FAST), Palliative Performance Scale (PPS) and the 
Karnofsky Performance Scale score. 11 
 
Patients who may benefit from hospice services include those who are terminally 
ill (i.e., life expectancy is six months or less) and who require services for the palliation 
or management of the terminal illness and related conditions. 12 The physician must 
certify (i.e., validate) that the patient is terminally ill and has a life expectancy of six 
months or less to live, if the disease follows its expected course. Certification from the 
physician is generally based on the physician’s or medical director’s clinical judgment 
regarding the normal course of the patient’s illness.16 Additionally, since medical 
prognostication is not always exact, documentation in the medical record must support 
the physician’s clinical judgment. 
 
The following clinical prognostic indicators have been identified as general 
predictors of end-stage illness (Royal College of General Practitioners [RCGP], 2006), 
and may be included in medical record17: 
 Multiple co-morbidities with no primary diagnosis, 
 Greater than 10% weight loss over six months, 
 General physical decline, 
 Serum albumin < 2.5 g/dL, 
 Reduced performance status (e.g., Karnofsky score < 50%), and 
 Dependence in most activities of daily living. 
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In the event of patient survival being longer than six months, the physician must 
recertify that the patient is terminally ill for the hospice benefit to continue. The fact that 
the patient lives longer than six months, is not a reason to terminate coverage of hospice 
services.18 
 
Levels of Hospice Care 
Hospice care is defined by the services and care provided, in addition to the 
setting in which these services are delivered. According to the Medicare Hospice Benefit, 
there are four levels of hospice care available: routine home care, continuous home care, 
respite care, and inpatient care. 14 More than 90% of the hospice services in the US are 
based in the patient’s home. 15 
 
Routine Home Care: Routine home care is the basic level of care provided by the 
interdisciplinary hospice team to support a patient with a terminal illness. It may be 
provided in a private residence, a hospital residential care facility, or an adult care home. 
It may also be provided in a nursing facility when the facility has a contractual agreement 
with the hospice agency. This level of care typically requires fewer than eight hours of 
primarily nursing care per day and is based on the patient’s individual needs. The nursing 
care need not be continuous. Family members and the hospice team work together to 
facilitate the role of family and friends as healthcare providers. Caregivers are taught how 
to care for the patient along with care that is provided by home health aids and skilled 
nursing. Typically, with this level of care, the nurse monitors the comfort level of the 
patient and works closely with the physician to adjust the treatment plan as needed. An 
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on-call registered nurse is available to provide phone support and make home visits as 
necessary. 
 
Continuous Home Care (CHC): Continuous home care is provided in a patient’s home 
and is often provided during a medical crisis that would otherwise require inpatient 
admission. For example, patients with out of control symptoms such as dyspnea, 
delirium, or pain may receive 24-hour nursing services temporarily until they are stable. 
A minimum of eight hours of primarily nursing care is required, half of which must be 
provided by a registered nurse, licensed practical nurse or nurse practitioner. The nursing 
care need not be continuous. 
 
Homemaker or home health aid services may also be provided to supplement 
nursing care. Nursing care in the hospice setting includes but is not limited to observation 
and monitoring, in addition to skilled care for pain and symptom control. Hospice 
medical directors can make home visits during this time as needed. 13 
 
Inpatient Respite Care: Inpatient respite care is short-term care (i.e., five days or less 
per benefit period) that is provided to relieve family members and other unpaid 
caregivers who care for the patient in their private residence. Respite care may be 
provided in a hospice facility, hospital or nursing home. 
 
General Inpatient Care/ Hospital-based care (HB): General inpatient hospice care is 
provided in an inpatient setting for the purpose of managing symptoms or to perform 
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procedures for pain control that cannot be performed in other settings. The inpatient 
services may be provided in a hospice inpatient facility, hospital facility, or nursing 
facility under the arrangement of a hospice agency. 14 
 
Different Types of Hospice Services 
Medicare mandates the following core health professional service teams on the 
hospice team:  
Nursing Care: These services must require the skills of a registered nurse or a licensed 
practical nurse under the supervision of a registered nurse, and must be reasonable and 
necessary for treatment of the patient’s illness or injury. Nursing care also includes 
services provided by a nurse practitioner who is not considered the patient’s attending 
physician. 
 
Medical Social Services: These services are provided by a social worker who is working 
under the direction of the physician. 
 
Physician Services: The physician services of the hospice medical director or physician 
member of the interdisciplinary team must be performed by a doctor of medicine or 
osteopathy. 
 
Counseling Services: Different types of counseling services that may be provided, 
include counseling on patient’s diet, bereavement services, psychological services, etc. 
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Short-term Inpatient Care: General inpatient care may be required for symptom 
management and pain control that cannot be provided in other settings. Inpatient care 
may be required for medication adjustment, observation or stabilizing treatment, such as 
psychosocial monitoring, or for a patient whose family is unwilling to permit needed care 
to be furnished in the home. 
 
Medical Appliances and Supplies: These services include medical appliances and 
supplies, drugs and biologicals used by the hospice team primarily for relief of pain and 
symptom control related to the patient’s terminal illness. 
 
Home Health Aide Services: Trained home health aides, under the supervision of a 
registered nurse, may provide personal care services and/or perform household services 
to ensure a safe and sanitary environment in the home. 
 
Physical, Occupational and Speech Therapy: These services may be provided for 
purposes of symptom control or to enable the patient to maintain basic functional skills 
and activities of daily living. Despite the election of hospice care services for end-of-life 
care, specific disease treatment may be required for a secondary illness. These treatments 
may be considered life-prolonging; however, they often eliminate adverse symptoms such 
as shortness of breath, physical fatigue and edema. Essentially, some treatments may be 
both disease-modifying and palliative. Hospice organizations may allow patients to 
receive treatments such as palliative radiation or chemotherapy, blood transfusion or even 
surgery, if necessary, to control symptoms.19 
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 Professional Pharmacist services as such are not specifically mandated as a core 
requirement.  However, the 2008 Medicare Hospice Conditions of Participation do 
require the services of a practitioner with the requisite skills to oversee the hospice 
medication-use process for hospice patients regardless of the hospice environment of 
care.  Thus, most hospices today utilize a pharmacist as the health care professional 
responsible to the interdisciplinary team to provide oversight of the medication use 
process and to provide medication therapy management for the hospice patient. 39 
 
Discharge from Hospice Services 
In some situations, it is appropriate to discharge a patient from hospice. If the 
hospice team determines the patient is no longer considered terminally ill, discharge from 
hospice is deemed appropriate. In addition, hospice discharge may also be appropriate if 
the patient refuses services or is uncooperative, moves out of the area, transfers to another 
hospice program, or chooses to “revoke” hospice services. 20 To revoke the election of 
hospice care, the patient must file a document with the hospice that includes a signed 
statement that the patient revokes the election for Medicare coverage of hospice care for the 
remainder of that election period and the effective date of that revocation. The patient forfeits 
hospice coverage for any remaining days in that election period. Upon revoking the election 
of Medicare coverage of hospice care for a particular election period, a patient resumes 
Medicare coverage of the benefits waived when hospice care was elected. An individual may 
at any time elect to receive hospice coverage. 39 In the event a patient is discharged from 
hospice, benefit coverage would be available under core medical benefits as long as the 
patient remained eligible for coverage of medical services. 21 It is recommended that the 
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hospice program have a discharge planning process taking into account the possibility a 
patient’s condition may stabilize or change, and hospice services would no longer be 
required. Furthermore, it is recommended that the patient and family are notified that a 
discharge is being considered in order to allow for necessary arrangements. Prior to 
discharge, the hospice must obtain a written physician discharge order from the hospice 
medical director. 20 
 
 Medications as a Component of Hospice Care 
Hospice programs use medications, medical equipment and supplies for symptom 
control and improvement in the patient’s quality of life.  The goal is to promote pain and 
symptom management to the greatest extent possible. 19 Each hospice patient presents 
unique, rapidly changing symptom clusters, often including pain, weakness, anxiety, 
dyspnea, anorexia, constipation, early satiety, fatigue, and dry mouth.22 Because 
treatment of hospice care is palliative and time is short, creative aggressive medication 
regimens are crucial. As allowed by the Food and Drug Administration (FDA), clinicians 
use FDA-approved drugs for any reasonable purpose.23  
 
Pain 
Despite available and effective treatments, some generalists fail to assess pain 
appropriately, hesitate to prescribe opioids, and hold inaccurate assumptions about pain 
tolerance and drug dependency.24 Hospice providers take reasonable pain-management 
efforts. Their actions are bolstered by federal guidelines and many states laws affirming 
patient’s rights to effective pain management.23 
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Pain often has multiple causes such as soft tissue injury, tumors, bone infiltration, 
and nerve damage. Because patient’s pain thresholds differ, no standard protocol exists. 
Most hospice programs follow the World Health Organization’s 3-step analgesic ladder, 
which provides relief for 70% of patients 25, 26 : 
 A nonopioid for mild-to-moderate pain  
 A weak opioid for moderate-to-severe pain with a nonopioid adjuvant 
 A strong opioid for severe pain with a nonopioid adjuvant. 
 
Opioid doses are not reduced solely for hypotension, decreased respiratory rate, or 
consciousness; optimal comfort defined by patient preference is the goal. Oral 
administration is preferred, to avoid painful injections, but medications can be 
administered through a different route if the patient cannot take them orally.27 For bone 
pain, approximately, 40% of patients find relief with radiation therapy.28 Adjunctive 
therapy is often utilized to help manage other symptoms.30  
 
Patients sometimes plead for rapid death if pain or symptom management is 
inadequate.31 In cases of retractable pain, the American Academy of Pain Medicine's 
position is unequivocal: “In rare circumstances, when pain and suffering are resistant to 
treatment, sedation may be therapeutic and medically appropriate to obtain relief if 
consistent with the expressed wishes of the patient.” 32 
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Fluid Balance 
End-stage intravascular problems often lead to fluid imbalance and edema. 
Nausea and vomiting also contribute to imbalances. Rehydration therapy can worsen 
edema and lead to skin breakdown.30 Practices such as offering small amounts of liquid 
or ice chips are often used as alternatives to intravenous (IV) therapy.30 However, IV 
hydration may be employed to hasten excretion of drug metabolites and provide relief.29 
 
Dyspnea 
Dyspnea, affecting up to 70% of hospice patients, can be a frightening experience. 
Labored breathing, breathlessness, and gasping suggest hypoxia, but most hospice 
patients are not hypoxic. Supplemental oxygen may provide little relief. Causes are often 
related to pulmonary edema, obstruction, anemia, electrolyte imbalance, cardiac 
decompensation, respiratory failure, anxiety, and lymphangitis. If possible, underlying 
causes should be corrected. Keeping the room cool, employing stress-management 
techniques, and helping the patient relax also help. Low dose opioids and anxiolytics 
(usually benzodiazepines) are most commonly used and are effective at relieving 
dyspnea.23, 24, 29 
 
Delirium 
Delirium, an acute state of confusion, disorientation, and severe cognitive 
impairment—may be drug-induced or a consequence of dyspnea, hepatic insufficiency, 
vitamin deficiencies, or hypoalbuminemia.24 Haloperidol, risperidone, olanzapine, and 
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lorazepam are often helpful. Clinicians might select a more sedating neuroleptic such as 
chlorpromazine for patients experiencing refractory delirium.29  
 
Cachexia 
Many terminal diseases end with cachexia or wasting. Cachexia is loss of body 
mass that cannot be reversed nutritionally, even if the affected patient consumes more 
calories, lean body mass will be lost, indicating there is a fundamental pathology in place. 
Prevalence varies with pathology; lung cancer and AIDS often cause cachexia.24, 34, 35 
 
Agents that increase protein synthesis and decrease proteolysis often are helpful, 
including corticosteroids (which improve anorexia but not cachexia), and megestrol 
acetate and the preferred medication, mirtazepine.30 
 
Other Symptoms 
Imminent death is heralded by a plethora of problems: constipation, diarrhea, skin 
breakdown, infections, and weakened immunity. Each terminal illness presents its own 
symptom constellation, many of which are iatrogenic. Not all problems are physical; 
anger, depression, and anxiety are common and minimize quality of life. Anxiolytics and 
antidepressants fortify psychological supports, but fast onset of action is imperative. For 
this reason, clinicians often prefer methylphenidate over other medications requiring 
weeks to achieve maximum clinical impact.30 
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Procedures for Dispensing and Administering Medications 
Once a patient is certified as terminally ill with six months or less to live and 
elects hospice services, an initial plan of care must be established, and all treatment of the 
patient’s terminal illness must be provided by or through the hospice. Qualified personnel 
must perform all services. 18 
 
 The hospice provides appropriate methods and procedures for the dispensing 
and administering of drugs and biologicals. Whether drugs and biologicals are obtained 
from community or institutional pharmacists or stocked by the facility, the hospice is 
responsible for drugs and biologicals for its patients, insofar as they are related to the 
terminal diagnosis and for ensuring that pharmaceutical services are provided in 
accordance with accepted professional principles and appropriate Federal, State, and local 
laws. 38 
 
    The procedure for the dispensing and administering of drugs is as follows 
(Conditions of participation by CMS): 
    (1) Licensed pharmacist: It is mandatory for a hospice to employ a licensed 
pharmacist; or have a formal agreement with a licensed pharmacist to advise the hospice 
on ordering, storage, administration, disposal, and record keeping of drugs and 
biologicals. 39 
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    (2) Orders for medications: It is the responsibility of a physician to order all 
medications for the patient. For verbal medication orders, the physician must deliver the 
orders to a licensed nurse, pharmacist, or another physician; then the individual receiving 
the order must record and sign it immediately and have the prescribing physician sign it 
in a manner consistent with good medical practice. 41 
 
    (3) Administering medications: Medications should be administered only by one of 
the following individuals: 
 (i) A licensed nurse or physician. 
 (ii) An employee who has completed a State-approved training program in 
medication administration. 
 (iii) The patient if his or her attending physician has approved. 
 
    (4) Control and accountability: The hospice must  have procedures for control and 
accountability of all drugs and biologicals throughout the facility. Drugs should be 
dispensed in compliance with Federal and State laws and records of receipt and 
disposition of all controlled drugs are to be maintained in sufficient detail to enable an 
accurate reconciliation.  It is the duty of the pharmacist to determine that drug records are 
in order and that an account of all controlled drugs is maintained and reconciled. 41 
 
    (5) Labeling of drugs and biologicals: The labeling of drugs and biologicals is based 
on currently accepted professional principles, state and federal regulations, and includes 
the appropriate accessory and cautionary instructions, as well as the expiration date when 
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applicable. 
 
    (6) Storage: In accordance with State and Federal laws, all drugs and biologicals are to 
be stored in locked compartments under proper temperature controls and only authorized 
personnel may have access to the keys. Separately locked compartments should be 
provided for storage of controlled drugs (Schedule II of the Comprehensive Drug Abuse 
Prevention & Control Act of 1970) 42 and other drugs subject to abuse, except under 
single unit package drug distribution systems in which the quantity stored is minimal and 
a missing dose can be readily detected. An emergency medication kit is kept readily 
available. 
 
  (7) Drug disposal: Controlled drugs no longer needed by the patient are disposed of in 
compliance with State requirements. In the absence of State requirements, a pharmacist 
and a registered nurse dispose the drugs and prepare a record of the disposal.41 
 
Value of Pharmacists in Hospice Care 
The American Society of Health-Systems Pharmacy (ASHP) suggests that high-
quality hospice and palliative care requires both, traditional and expanded pharmacist 
activities, including a variety of clinical, educational, administrative, and support 
responsibilities such as 40: 
 Assessing the appropriateness of medication orders and ensuring the timely 
provision of effective medications for symptom control 
 Counseling and educating the hospice team about medication therapy 
 17 
 
 Ensuring that patients and caregivers understand and follow the directions 
provided with medications 
 Providing efficient mechanisms for extemporaneous compounding of nonstandard 
dosage forms 
 Addressing medication related financial concerns 
 Ensuring safe and legal disposal of all medications after death 
 Establishing and maintaining effective communication with regulatory and 
licensing agencies 
 
A pharmacist can also be useful in improving the cost-effectiveness of 
pharmacotherapy for symptom control in hospice care through patient-specific 
monitoring for drug therapy outcomes, recommending alternative drug products and 
dosage forms, minimizing duplicative and interacting medications, compounding of 
appropriate medications, improving drug storage and transportation, and educating staff, 
patients, and families about the most effective ways of handling and using medications. 
Systems for documenting these activities and determining cost-effectiveness/cost–
benefit/cost–utility ratios of medications used in the care of terminally ill patients are 
needed. Avoidance of admissions to hospitals or long-term-care facilities through 
improved symptom control is a highly desirable and cost-effective outcome of 
pharmaceutical care for hospice and palliative care patients. 
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PROBLEM STATEMENT 
 
Clinical pharmacists at hospices see an average of 10 drug-related problems per 
patient upon admission.57Studies have shown that as polypharmacy increases, the rate of 
drug-related problems increases as well.57 A few of these problems include medications 
prescribed with no indication, potential or actual adverse drug reaction detected, dose too 
high, dose too low, medications indicated but not prescribed and inappropriate 
medications.. 
 
If the medication is not appropriate for the patient, this may result not only in 
unnecessary medication costs, but also result, in high costs, and unnecessary suffering 
associated with untreated symptoms. For example, the use of antiemetics for 
nausea/vomiting due to constipation from opioids will be poorly efficacious and not cost-
effective.  Since the root cause of the symptom (nausea/vomiting) is constipation, 
medication for constipation should be prescribed, such as a laxative instead of an 
antiemetic. 
 
The appropriate selection of medications results in better symptom control, fewer 
nursing visits, fewer on-call demands, fewer hospitalizations and ER visits, and fewer 
medication-related liability issues. The use of unnecessary medications should be avoided 
in terminally ill patients, and hospice programs should not be burdened with costs related 
to unnecessary medication use, which can be easily avoided.  
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All hospices should consider employing clinical pharmacists. Some hospices 
employ full–time pharmacists, while others sub-contract for this service. Employing 
clinical pharmacists through the relationship of a Pharmacy Benefit Manager (PBM) for 
reconciliation of medication may be considered as the best option. United States PBMs 
administer prescription drug plans which provide over 3 billion prescriptions) for more 
than 210 million people (70% of entire U.S. population) as part of health coverage 
provided through Fortune 500 employers, health insurance plans, labor unions, and 
Medicare Part D.62 There are PBMs that partner exclusively with hospices and provide 
numerous services pertinent to hospices, such as clinical consultations, education 
programs,  management reports and summaries including but not limited to drug 
utilization review reports.  
 
PBMs emerged in the 1980s, primarily to provide cost-effective drug distribution 
and claims processing for the healthcare industry. The PBM industry further evolved in 
response to the significant escalation of healthcare costs in the 1990s, as sponsors of 
benefit plans sought to more aggressively contain their costs. PBMs developed strategies 
to effectively influence both supply and demand. Through purchase discounts, retail 
pharmacy networks, mail order pharmacy services, preferred drug list administration, 
claims processing and drug utilization review, PBM companies created an opportunity for 
health benefit plan sponsors to deliver prescription drugs in a more cost-effective manner 
while improving compliance with recommended guidelines for safe and effective drug 
use. 
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Despite many of advantages of PBMs, many hospices remain reluctant to employ 
PBMs for medication review.  Successful medication related interventions can bring 
substantial cost savings and effective therapies in hospice care. Further studies need to be 
conducted focusing primarily on the utilization and costs of medications, or impact of 
pharmacist-led intervention leading to cost-effectiveness in hospice care. 
 
OBJECTIVES OF THE STUDY 
 
The overall objective of this study was to identify and analyze medication related 
costs as well as medication utilization in hospice care. 
The specific objectives were: 
 
1. Describe patient-related and hospice-related characteristics such as gender, 
average length of hospice stay, primary diagnoses, average daily census, number 
of admissions per year, net operating revenues, inpatient unit (IPU) operating 
costs, and medication expenditures among hospice patients. 
2. Compare patient-related and hospice-related characteristics of five hospices in 
Ohio with National Hospice and Palliative Care Organization (NHPCO) data. 
3. Identify and analyze therapeutic drug classes with the most frequent utilization 
rates and largest percentage of expenditures in hospice care. 
4. Identify and analyze utilization and cost for medications in hospice care. 
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CONCEPTUAL FRAMEWORK 
 
 For our study, five hospices in Ohio agreed to participate and were requested to 
send their 12-month medication cost and utilization data. These five study hospices are 
non-profit organizations that employ a pharmacy benefit manager (PBM) for prescription 
drug programs. A PBM is a third party administrator of prescription drug programs. They 
are primarily responsible for processing and paying prescription drug claims. They are 
also responsible for developing and maintaining the medication formulary, contracting 
with pharmacies, and negotiating discounts and rebates with drug manufacturers. PBMs 
contract with managed care organizations, self-insured employers, insurance companies, 
unions, Medicaid and Medicare managed care plans, the Federal Employees Health 
Benefits Program and other federal, state, and local government entities to provide 
managed prescription drug benefits. Due to their larger purchasing pool for prescription 
drugs, PBMs can negotiate rebates and discounts on behalf of their clients. 
 
The PBM claims data have an advantage, for they can be used for a variety of 
purposes, including studying the care received by dying patients. Claims data generally 
encompass a wealth of variables which facilitate ease in identifying diagnoses and 
procedures, help in broadly looking at timing (specific days for hospitalizations, length or 
span of days for hospice, home care), and to determine intensity of hospice care (routine, 
continuous, or inpatient). 
 
For this study, PBM claims data were employed to conduct a retrospective study. 
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PBM claims data consist of information on drug costs and prescription drug count. Such 
claims data were collected and obtained from five hospices in Ohio. Annual data from 
January 1, 2007 through December 31, 2007 of the five hospices were combined to form 
a dataset which contains information regarding prescription medication utilization and 
their costs, including information on therapeutic class of medications, drug names, total 
cost and prescription medication count. The dataset comprises of at least 1,020 different 
medications classified under 250 (approx.) different therapeutic classes of medications. 
 
Additionally, hospice participants were asked to report data for the most recently 
available 12-month period, patient-related (gender and average length of stay) and 
hospice-related (number of admissions per year, pharmacy costs, physician salary, 
nursing salary and bereavement costs) characteristics. These reports were obtained 
individually from each hospice which assisted to understand patient demographics and 
the overall costs incurred in a hospice. 
 
Retrospective analyses of these PBM claims data were conducted to identify 
expensive specialty and even inexpensive maintenance medications. Such analyses can 
be conducted quickly regardless of the huge sample size of claims database and are 
relatively inexpensive to perform. These analyses helped identify the ten most frequently 
utilized and expensive therapeutic classes of drugs in a hospice. Furthermore, they also 
allowed us to examine the differences in prescription drug count and total cost by 
therapeutic class and by drug name for each hospice and for all hospices combined. 
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Besides, medication data from the five hospices were compared to one another to 
examine difference in medication use by hospices. 
 
NEED FOR THE STUDY 
 
The overall costs for hospice care to Medicare, other third party payers and 
patients may be less as compared to the costs incurred by conventional care, but the cost 
for medications in a hospice program could be high, which can be effectively reduced by 
medication review. Especially, with the introduction of the Affordable Care Act (ACA), it 
has become imperative for all health care institutions to provide patients with high quality 
services with minimal costs. Pharmacists specializing in hospice and palliative care are 
able to recommend appropriate and effective drug therapy as an alternative to high cost, 
high risk medications and produce cost-savings. The pharmacists also identify drug 
related problems (DRPs) which can influence better patient outcomes in hospice care. 
 
A technique to ensure that hospice patients gain maximum benefit from their 
medications, while simultaneously reducing the potential for harm and improve health 
outcomes is essential. Achieving these goals is at the heart of successful medication 
review that has been defined as a structured, critical examination of a patient's medicines 
with the objective of reaching an agreement with the patient about treatment, optimizing 
the impact of medicines, minimizing the number of medication-related problems, and 
reducing waste. 
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 It has also been assumed, although based on little high quality evidence, such 
measures will lead to important gains for health systems by reducing hospital admissions 
and inappropriate drug prescribing. Such gains hold great appeal for policymakers when 
taken in combination with the apparent benefits to patients.5 With this underpinning 
rationale in mind, medication reviews have been widely introduced and are increasingly 
undertaken by pharmacists operating separately from the physicians involved in 
prescribing decisions. 
 
Over the past five years, clinical trials have shown growing evidence of better 
outcomes generated due to interventions such as pharmacist-led medication review. These 
trials have varied in terms of target population (older people generally, or those with a 
specific disease), numbers of pharmacists, and location of the intervention (home, 
pharmacy, general practice, hospital, or a hospice). The primary outcome has also varied, 
including reduction of drug related problems, adverse drug reactions, hospital 
admissions, and/or improving medication appropriateness.65 
 
Medication review, like medications themselves, has the potential to yield 
benefits. This intervention delivered by professionals not primarily responsible for 
prescribing decisions such as Pharmacy Benefit Managers (PBM), should be expected to 
adequately demonstrate not just effectiveness but also cost-effectiveness before being 
introduced more widely. PBMs employ variety of tools to demonstrate and produce 
effective pharmacy benefit management, thereby recommending utilization of cost-
effective medications. Formularies are central to these management efforts. By placing 
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such cost-effective medications on hospice formulary, PBMs facilitate control of costs to   
hospices. 
 
Previous studies have evaluated the impact of pharmacist-led interventions in 
terms of clinical outcomes. However, there is a dearth of information related to 
economics of medications in hospice care. Thus, there is a need for studies that place 
emphasis on reviewing and analyzing the costs and utilization of usage of medications. 
 
Since the five hospices in Ohio employ preferred drugs recommended by 
pharmacists following a medication review to identify potential drug-related problems 
(DRPs) and encourage cost-effective drug utilization, this study will provide an in-depth 
knowledge of the cost of medications in hospice and study the impact of pharmacist-led 
interventions on cost savings in hospice care. In addition, PBM claims data obtained 
would have important implications for pharmacist’s interventions facilitating 
identification of important medications utilization issues that contribute to significant 
expenditures in hospice care, which will serve as a benchmark in the field of hospice. 
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CHAPTER 2 
LITERATURE REVIEW 
 
A comprehensive review of the literature on hospice care in United States was 
conducted to identify articles published from 1984 to 2007. The articles were accessed 
from search engines such as Medline and Google Scholar. Initial or primary searches 
were made using the keywords ‘hospice care’ which resulted in a total of 3,674 articles, 
out of which only 59 articles were found to be useful for the study. After reviewing those 
articles, only 16 articles relevant to costs and medication utilization of hospice care were 
used for the study. Further secondary searches were made using keywords such as 
‘hospice medication use/utilization’, ‘hospice drug use’, ‘palliative care medications’, 
‘hospice patient characteristics’, ‘hospice care costs’, ‘hospice care economics’, ‘hospice 
cost-effectiveness’, ‘terminally ill costs’, ‘terminally ill economics’, ‘pharmacists and 
hospice’, ‘pharmacy benefit management and hospice’, and ‘pharmacist-led intervention 
and hospice’. A combined total (articles found from primary and secondary 
investigations) of 27 articles were used in this research paper. 
 
The term ‘hospice’ was coined hundreds of years ago, but has become familiar 
worldwide only recently. The term “hospice” was used in the 1800s for places where 
travelers used to rest. It was only later in early 1900s that hospices were used to provide 
care for the dying or terminally ill through simple palliative and supportive services. The 
first hospice program in the US was established in 1974. Hospices promoted peace, 
comfort, and dignity, rendering philanthropic support to provide care to terminally ill or 
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dying patients. Furthermore, hospice emerged as a philosophy or concept of care and the 
use of hospices increased drastically after the provision of partial reimbursement to 
Medicare hospice patients by Federal Legislation (1983).43 
 
It was after 1983, that several research studies on hospice care were conducted, 
that focused on the characteristics of patients using hospice services and on the 
economics of hospices. The first major development in the structure of hospice services 
was the National Hospice Study (NHS, 1984).44 In the course of this study, definition and 
structure of hospices emerged. This study provided data on hospice patient characteristics 
and expenditures which demonstrated that the model of hospice which evolved from the 
original philosophy, under Medicare guidelines, differed substantially in services and 
structure from conventional medical care of the terminally ill or dying patients. Several 
studies were conducted later on a smaller scale that examined the same or various aspects 
of hospice care. 
 
Characteristics of Hospice Patients 
 Hospice services are available to any individual electing the service regardless of 
his/her age, race, marital status, income level, diseases, etc. In recent years, there has 
been considerable increase in the use of hospice services by younger patients (younger 
than 65 years). In 2006, an estimated 17% of patients younger than 65 years were 
receiving hospice care compared to less than 10% in 1984.45 
  
 Low hospice care utilization rates have been observed among the non-Caucasian 
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population. The number of African-American patients utilizing hospice services dropped 
from 8.1% in 2002 to 7.5% in 2005, although, this percentage moved up to 8.2%  in 
2006. Several causes for underutilization among the African-Americans and other ethnic 
minority groups have been proposed. These include the lack of knowledge about hospice 
services, different cultural beliefs; and high costs of health care. 46 
 
Utilization of hospice services is affected by geographical location. Previous 
studies suggest that utilization of hospice services is positively associated with ‘urbanity’ 
indicating that more patients utilize hospice services in urban areas than in rural areas. 
This positive association with urbanity in the utilization of hospice service is potentially 
due to the lack of awareness about hospice services in rural areas; and that there is more 
awareness among the urban population which leads to more utilization & expenditures on 
health-related issues as compared to rural population. 47 
 
Length of Stay in Hospice/Length of Hospice Service (LOS) 
 Typically, the length of hospice stay or length of hospice services (LOS) is not 
longer than 90 days. The place of delivery of hospice service largely influences the LOS.  
It was observed that the inpatient respite care and hospital-based care have shorter LOS 
compared to home-based care.  The skewed length of hospice service was found to be 
72.5 days for hospice service rendered at home and 62.3 days for hospice service 
rendered at hospitals.48 Medicare hospice data shows that the LOS for Medicare hospice 
recipients decreased from early 1990s to 2001. 49 (Refer Figure 1) 
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Figure 1. Variation in length of service provided to Medicare hospice recipient. 
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Disease Diversity Among Hospice Patients 
 Patients suffering from various diseases can elect to receive hospice care. Unlike 
previous years, when hospice programs were in the process of nationwide establishment 
(1985), cancer patients accounted for most (90%) of the population; now, a higher 
number of   non-cancer patients are observed electing for hospice services. These may 
include patients suffering from various non-cancer diseases such as heart diseases, lung 
diseases, dementia including Alzheimer’s disease, stroke, coma, HIV/AIDS, liver 
diseases, etc.50 In 1992, non-cancer patients accounted for 24% of all hospice patients. 
Furthermore, based on 2006 NHPCO  estimates, the percentage for non-cancer patients 
electing hospice services has grown steadily from 39% in 2000 to 50% in 2002 to 55.9% 
in 2006. 51 (Refer Figure 2) 
 
Cost of Hospice Services 
 The Hospice Association of America suggests that the overall cost of hospice care 
per patient increased from $3,020 (1989) to $ 6,228 (2001) (Refer Figure 3).52  With this 
kind of rising cost of health care, a considerable concern in the US has emerged in the 
past decade. Efforts have been made to minimize health care costs, which in turn impose 
pressure on the hospice, to deliver optimum care to patients at a lower cost.53 
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Figure 2. Variation in proportion of cancer patients versus the proportion of non-
cancer patients enrolled in hospice programs from 1985 to 2006. 
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Figure 3: Costs of hospice care per patient in the United States from 1989 to 2001. 
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Medication Utilization 
Pain management and symptom control are two of the most important goals of 
end-of-life care, and the use of opioids for this purpose is extremely common in hospices. 
Previous studies have suggested morphine to be the most utilized drug for pain control. 
Approximately, 70% of hospice patients receive morphine for pain control. Moreover, a 
fairly strong correlation exists between morphine dosage and some clinical-demographic 
data. A study revealed that male and nonwhite patients required slightly higher dosages 
than others.25 In addition, primary breast and genitourinary cancers, as well as metastases 
to bone and spinal diseases, were associated with higher morphine dosages. 54 Other 
analgesic medications that are most commonly used in a hospice setting are long-acting 
morphine sulfate (25.4 %), acetaminophen and hydrocodone combinations (20.1 %) and 
NSAIDS (17.1 %).55 
Constipation is a common problem for hospice care patients and can generate 
considerable suffering for patients due to both the unpleasant physical symptoms and 
psychological preoccupations that can arise. Constipation may arise as a side-effect of 
opioid therapy. 57 In an effort to find a relationship between laxative use and opioid use 
among the terminally ill patients, Sykes (1998) found that laxatives were required by 
87% of patients taking oral strong opioids and 74% of those on weak opioids. The most 
commonly prescribed laxatives/cathartics were senna, docusate sodium, etc.58 
 
  Anxiety and depression are other commonly observed symptoms among 
terminally ill patients. These symptoms are experienced among a quarter of terminally ill 
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patients. Patients may be treated by use of anti-anxiety medications and antidepressants at 
a hospice. However, use of the antidepressant medications for treating depression and, in 
some cases, anxiety disorders has not been well studied in hospice. Some of the 
antidepressant medications may also serve as adjuvant therapy in pain management.59 
 
 A study by Williams (1999) analyzed the antidepressants prescribed among the 
terminally ill. It was found that the majority of patients who were on anti-depressant 
medications suffered from cancer such as lung cancer (26%), breast cancer (43%), 
colorectal cancer (15%) and prostate cancer (11%). The most commonly prescribed 
medications were selective serotonin reuptake inhibitors (70%) and tricyclic 
antidepressant medications.60 
 
When all other possible interventions have failed for the relief of one or more 
intractable symptoms (physical, psychological and spiritual) and when relief of refractory 
symptoms need to be achieved in terminally ill patients, palliative sedation must be 
considered. Rosseau PC (2004) studied the medication utilized for palliative sedation in 
hospice care. Benzodiazepines and barbiturates were found to be the most commonly 
administered medications for achieving palliative sedation in terminally ill patients. 
Midazolam, lorazepam, haloperidol, pentobarbital, phenobarbital and propofol were the 
recommended medications for achieving palliative sedation. 56 
 
A study by Haughtevd and colleagues (1994) made efforts to evaluate the cost to a 
hospital pharmacy department of providing pharmaceutical services for a hospice 
program. Drug acquisition costs were tabulated for all prescriptions dispensed to patients 
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in the hospice program from April 1, 1992, to March 31, 1993. Direct time studies were 
conducted to determine the average personnel time involved in dispensing a prescription 
for a hospice patient. To determine the personnel time associated with auxiliary activities, 
self-reporting and work-sampling techniques were used. Indirect and delivery costs were 
also calculated. Relevant resource inputs were identified, measured, and valued by using 
both observation and pharmacy records. A total of 5,640 hospice prescriptions were 
dispensed by the outpatient pharmacy; representing 30% of all prescriptions dispensed. 
The average cost of dispensing a hospice prescription was $14.91.The total annual cost of 
providing pharmaceutical services to the hospice's patients was $196,607, and the total 
annual reimbursement received from the hospice program and self-paying patients was 
$155,623; therefore, costs exceeded revenues by $40,984. The cost to a pharmacy 
department of providing pharmaceutical services to patients in a hospice program 
substantially exceeded revenues. 61 
 
In general, very few studies have looked into the areas of medication utilization, 
especially the costs of these medications for hospices. Since there were no data 
describing these costs for hospice programs in 2004, Nowels and colleagues (2004) 
conducted a cross-sectional survey study in hospices of the Population-based Palliative 
Care Research Network (PoPCRN). PoPCRN was formed in 1998 at the University of 
Colorado, Denver School of Medicine as a means for conducting on-going studies of care 
at the end of life. Specifically, their aim is to facilitate structured and rigorous exploration 
of issues of importance to patients, families, caregivers, and providers in palliative care 
and hospice settings. Since its inception, PoPCRN has grown to include 279 
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hospice/palliative care organizations from 49 states in the United States and also includes 
Canada, Australia, Italy, Portugal, and the UK.   
 
The Web-based survey consisted of 31 questions describing structural and 
operational features of respondent organizations, aspects of the supply and delivery of 
pharmaceuticals for hospice patients, cost controls employed by the respondent 
organization, drug costs per patient per day (PPPD), perceived trends in drug costs, and 
factors contributing to those trends. Participating hospices were asked to report their most 
recent 12-month data. The study analyzed data from 34 hospices concerning their 
pharmaceutical cost trends. Most respondents reported higher pharmaceutical-related 
costs between 1998 and 2002, but a significant minority reported that their costs had 
decreased. 
 
Pharmaceutical costs reported in the 2004 study varied by patient setting with 
median daily costs of $8 (long-term care setting from), $11 (home-care hospice setting), 
$11.31 (routine level of care), $15 (general inpatient care), and $18 (inpatient care). The 
respondents identified a variety of medications and their delivery systems as contributing 
to their major medication costs. Long-acting opioids and continuous-infusion delivery 
systems were the two most significant contributors. Strategies to control errors included 
screening drug on admissions, a preferred drug list, a consulting pharmacist, efficacy 
criteria for continuation of high cost drugs, a formulary, a pharmacist on staff of hospice, 
and more restrictive admission policies. Certain restrictions were developed on some 
drug classes such as cell stimulants, chemotherapy, total parenteral nutrition, 
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bisphosphonate, anticoagulants, cardiac pressor agents, intravenous fluids for hydration, 
opioids-long acting, antibiotics, continuous infusion, and parenteral medications.62 
 
Lee and McPherson (2006) studied the value of pharmaceutical care 
recommendations made by consultant pharmacists and their outcomes. The study was 
conducted at three hospice programs, and the investigators were consultant pharmacists 
who shared the responsibility of providing drug therapy recommendations to these three 
programs. They conducted literature searches to determine if any tools had been 
developed to evaluate recommendations made by pharmacists in clinical practice settings. 
One tool was identified and adapted for use in a hospice clinical setting. Drug-related 
problems (DRPs) (n = 98), clinical interventions (n = 87), and outcomes data were 
collected by two hospice consultant pharmacists and evaluated by a panel of experts 
using the assessment tool. Ninety-eight interventions were collected and evaluated. 
Eighty-seven of the 98 interventions were classified as clinical interventions with specific 
therapeutic goals established. Of these 87 interventions, 73 (84%) were accepted by the 
prescriber and 56 (77%) out of the 73 helped achieve the therapeutic goals. An additional 
of 6 (8%) interventions partially achieved the therapeutic goals. Over 75% of all of the 
pharmacists' recommendations achieved their intended therapeutic effect, which resulted 
in better management of the patients' physical symptoms. None of the accepted 
recommendations resulted in the patient having an adverse effect. Overall agreement 
between raters for severity and value was moderately high, 60-70% and 63-80%, 
respectively.63 
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Guignard (2003), studied the economic impact of community pharmacists' 
interventions following the detection of problems related to nonsteroidal anti-
inflammatory drugs (NSAIDs), whether in a prescription or self-medication format. The 
evaluation focused on the gastroduodenal adverse events that could be avoided and the 
subsequent savings of healthcare resources spent on treating these adverse effects. A 
previous study conducted during a 12-week period in 924 French community pharmacies 
provided the number of interventions for drug-related problems concerning NSAIDs. A 
simulation model was constructed to compare 2 strategies: a systematic pharmacist's 
intervention and the absence of intervention. The base-case patient was assumed to have 
been taking an NSAID for 3 months. The model's inputs were extracted from medical 
literature and from an institutional medical database.  In this study, 608 interventions were 
the results of NSAID-related problems. All of these interventions reduced the risk of 
gastrointestinal adverse events and avoided a total cost of Euros37, 300. This model 
indicated that the dispensing of NSAIDs by pharmacists and related pharmaceutical care 
activities have a positive impact by reducing the number of gastrointestinal complications. 
The model quantifies the costs thus avoided. It also underlines the necessity of effective 
collaboration between the prescriber and the pharmacist if optimal patient management is 
to be achieved. 64 
 
The above studies suggest that greater efficiencies, a change in the pricing 
structure, or both may be necessary to control drug costs. However, this is possible by 
employing a consultant pharmacist or a pharmacist on staff of the hospice. High-quality 
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hospice and palliative care requires both traditional and expanded pharmacist activities, 
including a variety of clinical, educational, administrative, and support responsibilities. 
 
 Our study is based on analyzing the utilization and costs of medications in 
hospice care that employ PBMs to manage drug benefits and it would be interesting to 
observe the cost-savings produced by these hospices. 
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CHAPTER 3 
METHODOLOGY 
 
Previous chapters illustrated the role of pharmacists in hospice care and the PBM-
hospice relationship. This chapter will discuss the data used for the study and the 
methods used to achieve the study objectives. 
 
Pharmacy Benefit Manager’s (PBM) claims data are one of the “best sources” of 
information for identifying key components of an effective pharmacy plan and for 
measuring results that reside within the data. It facilitates conducting retrospective 
analysis to not only find medication utilization and costs, but also help in predicting 
future costs, trends and needs. 
 
To study our objectives, five hospices in Ohio agreed to participate in the research 
study and made their PBM claims data available to the researchers. These hospices 
employ a PBM with consultant pharmacists to review medications, plan a formulary, and 
help reduce medication costs. PBM claims data for year 2007 (January 1, 2007 through 
December 31, 2007) were obtained individually from these five Ohio hospices and 
combined into a single dataset. The data was received in Excel format which was sorted 
by number of prescriptions in descending order (Prescription [Rx] Count). The data 
provided retrospective insurance claims data for the prescriptions fills of patients served 
by the five hospices. The study was then conducted post approval of Duquesne 
Institutional Review Board. 
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To maintain confidentiality, the five hospices were named hospice 1, hospice 2, 
hospice 3, hospice 4, and hospice 5. The dataset reflects utilization and expenditures 
related to 246 therapeutic classes and 1,020 medications utilized in these five hospices 
and is comprised of different variables such as therapeutic class, drug names, prescription 
count (Rx Count), and total cost. These variables helped identify therapeutic classes and 
medications that contribute to most frequent utilization rates and largest percentage of 
expenditures in hospice care. These variables were defined for the study as follows: 
 
Therapeutic Class of Drugs  
The medications utilized in each of the hospices are classified under 246 different 
therapeutic classes. This variable will help identify the different therapeutic classes of 
medications utilized in hospice care. 
 
Drug Names 
Drug names are the prescription medications dispensed to a hospice patient served at a 
hospice agency. The data includes information on 1,020 different drug names and these 
drug names were generic, brand or both. This variable was used to identify the important 
medications categorized under different therapeutic classes. 
 
Prescription (Rx) Count  
Each dataset received was sorted by prescription count. This variable is defined as the 
total number of prescriptions dispensed for each medication in a hospice. It is an ordinal 
variable and the value of Rx count ranges from 1 - 990. 
 42 
 
Total cost 
This variable is defined as the sum of the cost of prescriptions for each medication. It is 
an ordinal variable. In the study, this variable was used to compute the total cost for all 
medications prescribed in a hospice and was also used to identify important therapeutic 
classes and medications with largest percentage of expenditures. 
 
STATISTICAL REPORTS 
 
In addition to the claims data, statistical reports for hospice patient-related 
(gender, primary diagnoses,  and average length of stay) and hospice-provider (number of 
admissions per year, average daily census, total patient days, nursing salary, physician 
salary, bereavement costs and pharmacy costs) characteristics were obtained separately 
from each hospice. A mean for each of these characteristics obtained from the combined 
data of five hospices was reported and compared to 2007 National Hospice Palliative 
Care Organization (NHPCO) data. . 
 
NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION (NHPCO) 
REPORTS 
 
Founded in 1978, the National Hospice and Palliative Care Organization is the 
oldest and largest nonprofit public benefit organization devoted exclusively to hospice 
care. NHPCO is dedicated to promoting and maintaining quality care for terminally ill 
persons and their families, and to making hospice an integral part of the U.S. health care 
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system. NHPCO collects data annually from nationwide hospices to provide reports or 
summary on different aspects of hospice care such as characteristics of patients and 
hospice-provider, costs components of hospice care, etc. 
 
In order to compare the hospice in Ohio with hospices nationwide, the 2007 
NHPCO Facts and Figures Report was utilized. NHPCO provides comparative reporting 
for the following tools that evaluate clinical care and services: the Family Evaluation of 
Hospice Care (FEHC), the Family Evaluation of Bereavement Services (FEBS), the 
Family Evaluation of Palliative Care (FEPC), and the End Result Outcome Measures 
(EROM). NHPCO offers agency and national level reporting for the Survey of Team 
Attitudes and Relationships (STAR), the only job satisfaction tool specific to the hospice 
field. NHPCO also provides results for the National Data Set (NDS) that are reported at 
the national and state level. Both STAR and the NDS are valuable organization and 
program evaluation tools. 
 
In order to address the objectives of the present study, the 2007 annual report of 
NDS was utilized. The NDS is comprised of program level descriptive statistical 
information that provides a comprehensive picture of hospice operations and care 
delivery. NDS data are used to answer key questions such as who is providing hospice 
care, who are the patients receiving that care, and how much and what kind of services 
were provided. NHPCO releases its findings on an annual basis to the media and key 
governmental agencies as well as members. 
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The primary source of these findings are the hospice and palliative care providers 
who participate in NHPCO’s National Data Set (NDS), an annual online survey 
supported by many of their state organization partners. Data from the NDS survey is 
supplemented by information NHPCO gathers from other sources. In general, the fact and 
figures report provides an annual overview of important trends in the growth, delivery 
and quality of hospice care across the country. The overview provides specific 
information on: 
 Hospice patient characteristics (e.g., total patients served, gender, age, ethnicity, 
race, primary diagnosis, and length of service); 
 Hospice provider characteristics (e.g., total number of providers, organizational 
type, size, and tax status); 
 Location and level of care; and 
 Role of paid and volunteer staff. 
Hospice Patient-related Characteristics 
Hospice patient-related variables that were included in the analysis were gender, 
length of service (LOS) and primary diagnoses. These variables are described as: 
 
Gender 
The variable is described as indicator of sex, and is utilized in this study to identify the 
gender of the hospice patient. 
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Length of Service (LOS)   
Mean LOS and median LOS were obtained from the hospices to find the average LOS 
provided to hospice patients. LOS is calculated from the date of enrollment to hospice 
service until the death or discharge of the patient from the hospice service. 
 
Primary Diagnoses 
Primary diagnoses were used to identify the terminal disease, for which is the reason for 
which they were enrolled for hospice care. Primary diagnoses were categorized into 
cancer and non-cancer. Non-cancer category was further sub-categorized into heart 
diseases, dementia/Alzheimer, lung diseases, kidney diseases, HIV/AIDS, stroke/come, 
ALS, debility unspecified and other. 
 
Hospice Provider-related Characteristics 
These include all the characteristics of a hospice agency such as average daily 
census, number of admissions per year, total patient days, net operating revenues per 
year, annual inpatient unit operating costs, annual pharmacy costs, physician salary, 
nursing salary and bereavement costs. 
 
Number of Admissions Per Year 
It is defined as the total number of patients enrolled for hospice services per year. 
 
Average Daily Census (ADC) 
Average daily census represents the average number of eligible patients receiving hospice 
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care service on a given day, inclusive of all patients receiving home care and in inpatient 
unit. In general, it is the average of all patients enrolled for hospice care per day 
regardless of the place where service is provided. 
 
Net Operating Revenues 
This is the amount accrued by net sales or other regular income related to the operations 
of a hospice care agency. 
 
Inpatient Unit (IPU) Operating Costs 
This term includes the costs that are associated with all the services provided at a hospice 
inpatient unit such as cost of a room/bed. 
 
DATA ANALYSIS 
 
The data analysis was conducted using SPSS (version 15.0). The data was 
transferred from Excel to SPSS for ease of manipulating data and conducting statistics. 
Data were then checked for accuracy and missing data or incorrect data (3%) were 
deleted. The first two objectives of the study were achieved by conducting a statistical 
report for year 2007. For all the other study objectives, PBM claims data from all study 
hospices combined for year 2007 was utilized. 
 
Objective 1: Describe patient-related and hospice-related characteristics such as gender, 
average length of hospice service, primary diagnoses, average daily census, number of 
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admissions per year, net operating revenues, inpatient unit (IPU) operating costs and 
pharmacy costs. 
Five statistical reports provided by the five hospices for year 2007 were utilized to 
achieve this objective. A mean for each of the patient-related and hospice-related 
characteristics was calculated from the five statistical reports obtained from the five 
hospices in Ohio. 
 
Objective 2: Compare patient-related and hospice-related characteristics of the five 
hospices in Ohio with NHPCO data. 
For this objective, statistical reports from the five hospices as well as the annual reports 
of NHPCO for year 2007 were used. The mean or average for the characteristics obtained 
from objective 1 was used to compare with NHPCO data. The characteristics that were 
compared were gender, average length of hospice service (LOS), primary diagnoses, 
average daily census, and total patient days. 
 
Objective 3: Identify therapeutic drug classes and medications with the most frequent 
utilization rates and largest percentage of expenditures in hospice care. 
A) For combined dataset 
Combined PBM claims dataset from all study hospices was used to achieve this 
objective. Descriptive analyses were conducted to identify ten therapeutic classes based 
on Rx count and total cost. The frequencies (sum) of Rx count and sum of the total costs 
for medications under each therapeutic class were computed. The ten therapeutic classes 
with highest Rx count and ten therapeutic classes with highest total cost were reported. 
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Similar statistics were conducted to identify ten medications based on Rx Count and total 
cost and results were reported. 
B) For individual hospice data 
Individual hospice data for hospice 1, hospice 2, hospice 3, hospice 4, and hospice 5 were 
used for this objective. Descriptive analyses, similar to objective for combined dataset 
were conducted to identify five therapeutic classes and five medications based on Rx 
count and total cost for each of the hospice. 
 
Objective 4: Further analyze medication costs and utilization rates under the identified 
therapeutic class of medications. 
Descriptive analyses were conducted to find frequencies (sum) of Rx count and total cost 
for each medication under each of the ten different identified therapeutic classes. Five 
medications whose frequency of use contributes to largest expenditures under the 
identified therapeutic classes were reported. 
 
The next chapter will discuss the results obtained by making use of the data and 
methodology. 
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CHAPTER 4 
RESULTS 
 
Previous chapters provided an overview of hospice care, outlined the specific 
study objectives, discussed some studies that have analyzed hospice characteristics and 
medication utilization in hospices, and described the study methodology and data 
sources. This chapter presents the results for each of the study objectives.  
 
 Individual PBM data from the Ohio hospices were employed to analyze 
therapeutic classes and medication utilization. Combined dataset from all five hospices 
were analyzed to study the overall medication utilization among these hospices. This 
combined dataset consisted of 1,020 different drug names under 246 therapeutic classes. 
 
For the study objective 1, statistical reports obtained from five hospices in Ohio 
for year 2007 were evaluated; while for objective 2, both statistical reports from five 
Ohio hospices and NHPCO reports were evaluated. 
 
Objective 1: Frequency of Patient- and Hospice-related Characteristics 
An average for all the patient- and hospice-related characteristics included in the 
statistical reports of study hospices in Ohio was calculated for the year 2007. Patient 
characteristics included gender, average length of hospice service, and primary diagnoses. 
Hospice-related characteristics included number of admissions per year, average daily 
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census, net operating revenues, inpatient unit [IPU] operating costs and pharmacy costs. 
 
Patient-related Characteristics 
There were approximately equal numbers of male (50.6%) and female hospice 
patients (49.4%). Mean length of stay (LOS) for year 2007 was 73.6 days, while median 
length of stay was 20.8 days among these hospices. Average number of patients with non-
cancer diagnosis (58.5%) was higher than those with cancer. Majority of patients referred 
to a hospice had a terminal diagnosis from cancer, heart diseases, lung diseases, stroke or 
coma and Dementia or Alzheimer’s disease (Refer Table 1). 
 
Hospice-related Characteristics 
The average number of admissions for the five hospices was 627 patients for year 
2007. Average daily census was 136 patients and total patient days averaged 51,350 days 
in these five hospices. Net operating revenues for the study hospices ranged from a 
minimum of $500,000 to $13.8 million per hospice. The major components of expenses 
identified in the hospices were annual physician salary costs, annual nursing salary costs, 
inpatient unit (IPU) operating costs, durable medical equipment (DME) costs, pharmacy 
costs and bereavement costs.  
 
For year 2007, average annual physician salary in each hospice was calculated to 
be $87,500. Around $930,000 was the average nursing staff salary costs, while vast 
differences in bereavement costs per hospice was observed. Average bereavement costs 
ranged from $4,500 to $222,000 per hospice. Durable medical equipment (DME) costs 
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varied from $170,000 to $600,000 per hospice, while the inpatient unit (IPU) operating 
costs varied from $700,000 to $1.7 million per hospice (Refer Table 2). 
 
A total of 59,174 prescription claims among the five hospices accounted for 
approximately $1.85 million worth of medications. Annual drug expenditures for each 
hospice averaged $371,750 and an average hospice medication cost per patient per day 
(PPPD) was $11.12 ($12.43 PPPD for home care and $8.5 PPPD for nursing care) for 
year 2007. With the exclusion of outliers such as enoxaparin injections, average hospice 
medication cost was $10.72 PPPD. 
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Table 1. Patient characteristics in five hospices of Ohio for year 2007 
Patient Characteristics N% 
Gender   
 Male 50.6 
 Female 49.4 
Length of Service (LOS)   
 Mean LOS 73.6 
 Median LOS 20.8 
Primary Diagnoses   
Cancer  41.5 
Non-Cancer  58.5 
 Heart Diseases 10.2 
 Liver Diseases 8.8 
 Lung Diseases 7.2 
 Kidney Diseases 5.4 
 HIV/AIDS 0.2 
 Stroke/Coma 3.3 
 ALS 2.3 
 Other Motorneuron 2.8 
 Debility Unspecified 11.2 
 Other 7 
N% = percentage of frequency. 
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Table 2. Characteristics of five hospices in Ohio for year 2007 
Characteristic Mean Range 
Number of admissions 627 patients 461 to 1,059 patients 
Daily census 136 patients 79 to 250 patients 
Total patient days 51,350 days 28,743 to 91,355 days 
Net operating revenues $7.5 million $500,000 to $13.8 million 
Physician salary $87,500 $83,748 to $263,000 
Collective Nursing salary $930,000 $867,723 to $1.1 million 
Bereavement costs $75,875 $4,500 to $222,000 
DME costs $237,500 $170,000 to $600,000 
IPU costs $980,000 $700,000 to $1.7million 
Annual drug costs $371,750 $67,580 to $ 763,413 
N= Sum of frequencies; DME= Durable Medical Equipment; IPU=Inpatient Unit 
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Objective 2. Compare patient- and hospice-related characteristics of the five Ohio 
hospices with 2007 NHPCO data. 
Statistical reports obtained from the five hospices were compared to the annual 
reports of NHPCO for year 2007. An average for patient and hospice characteristics was 
computed (objective 1) and compared with NHPCO data. The characteristics that were 
compared included average length of hospice service (LOS), primary diagnoses, gender, 
average daily census, and total patient days. 
The average daily census (136 patients) and total patient days (51,350 days) in 
five study hospices were, approximately, 1.5 times higher as compared to that of NHPCO 
data (90 patients and 31,300 days, respectively). Number of males (50.6%) and mean 
length of service (73.6 days) were slightly greater than those seen in the NHPCO data 
(46.1% and 67.4 days, respectively). Similar to NHPCO data (55.1%), number of patients 
with non-cancer diagnosis (58.5%) was found to be higher than those with cancer in these 
hospices. 
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Table 3. Comparison of Ohio hospice data to NHPCO data. 
Characteristics Ohio hospice data NHPCO data 
Average. daily census 136 patients 90 patients 
Total patient days 51,350 days 31,300 days 
Gender   
Males 50.60% 46.10% 
Females 49.40% 53.90% 
LOS 73.6 days 67.4 days 
Primary diagnoses   
Cancer 41.50% 44.90% 
Non-cancer 58.50% 55.10% 
LOS = Length of stay 
 
 
 56 
 
Objective 3: To identify ten therapeutic drug classes with most frequent utilization 
rates and largest percentage of expenditure in hospice care and analyze five most 
frequently utilized therapeutic classes. 
A) For combined dataset 
 Ten therapeutic drug classes with most frequent utilization rates and largest 
percentage of expenditure in hospice care 
Approximately 1,020 different drugs under 246 therapeutic classes were utilized in the 
five hospices. Descriptive analyses for therapeutic class sorted by Rx Count were 
conducted to find the frequencies for prescription count for medications. The sum of 
prescription counts for medications under each therapeutic classes were calculated. Ten 
therapeutic classes with highest frequency of prescription count were reported. The most 
frequently utilized therapeutic class of drugs, based on prescription drug volume (Rx 
Count) included analgesic-narcotics (16.3%) followed by laxatives-cathartics (7.9%), and 
anti-anxiety drugs (7.2%), glucocorticoids (4.3%), selective serotonin reuptake inhibitors 
(SSRIs) (3.8%), loop diuretics (3.7%), gastric acid secretion reducers (3.4%), 
antipsychotics - dopamine antagonists, butyrophenones (2.6%), anti-convulsants (2.3%), 
and alpha-2-receptor antagonist depressants (1.9%). Out of 246 therapeutics classes, 
these ten therapeutic classes are most frequently utilized in Ohio hospices and account for 
over 50% of entire prescription volume for year 2007 (refer Table 4). 
 
 
 
 57 
 
Table 4. Ten therapeutic classes sorted by prescription (Rx) count (combined 
dataset) 
Therapeutic Class Rx Count Total Cost 
Percentage 
% 
ANALGESICS,NARCOTICS 9,776 $315,926 16.35% 
LAXATIVES AND CATHARTICS 4,730 $43,730 7.91% 
ANTI-ANXIETY DRUGS 4,312 $86,690 7.21% 
GLUCOCORTICOIDS 2,612 $49,888 4.37% 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 2,305 $89,497 3.86% 
LOOP DIURETICS 2,260 $14,522 3.78% 
GASTRIC ACID SECRETION 
REDUCERS 2,040 $69,039 3.41% 
ANTIPSYCHOTICS,DOPAMINE 
ANTAGONISTS, 
BUTYROPHENONES 1,610 $24,092 2.69% 
ANTICONVULSANTS 1,354 $67,226 2.26% 
ALPHA-2 RECEPTOR 
ANTAGONIST 
ANTIDEPRESSANTS 1,172 $38,033 1.96% 
Grand Total 32,171 $798,642 53.81% 
Percentage (%) based on Total Rx Count.. 
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Similar analyses for therapeutic classes sorted by total costs in descending order 
were conducted to find the costs that were contributed by each therapeutic class. Top ten 
therapeutic classes that contributed to majority of drug expenditures were reported. These 
included several most frequently utilized therapeutic classes such as analgesics-narcotics 
(17%), selective serotonin reuptake inhibitor-SSRIs (4.8%), and anti-anxiety drugs 
(4.6%), gastric acid secretion reducers (3.7%), anticonvulsants (3.6%),and 
glucocorticoids (2.7%). A few therapeutic classes that were not frequently utilized but 
contributed to majority of the expenses included anti-psychotics - dopamine antagonists 
(5.2%), beta adrenergic and anticholinergic combinations (3.3%), heparin and related 
preparations (3.2%), antiemetic/antivertigo (2.7%). 
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Table 5. Ten therapeutic classes sorted by total cost (combined dataset) 
Therapeutic Class 
Rx 
Count Total Cost 
Percentage 
% 
ANALGESICS,NARCOTICS 9,776 $315,926 17.00% 
ANTIPSYCHOTICS,ATYPICAL,DOP
AMINE,& SEROTONIN 
ANTAGONIST 802 $96,023 5.17% 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 2,305 $89,497 4.81% 
ANTI-ANXIETY DRUGS 4,312 $86,690 4.66% 
GASTRIC ACID SECRETION 
REDUCERS 2,040 $69,039 3.71% 
ANTICONVULSANTS 1,354 $67,226 3.62% 
BETA-ADRENERGIC AND 
ANTICHOLINERGIC 
COMBINATIONS 468 $61,087 3.29% 
HEPARIN AND RELATED 
PREPARATIONS 99 $58,533 3.15% 
GLUCOCORTICOIDS 2,612 $49,888 2.68% 
ANTIEMETIC/ANTIVERTIGO 
AGENTS 698 $49,250 2.65% 
Grand Total 24,466 $943,159 50.74% 
Percentage (%) based on total costs. 
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Further, five most utilized therapeutic classes were analyzed to identify 
medications whose frequency of use contributed to majority of the expenses. Under 
therapeutic class analgesics-narcotics, medications such as morphine sulphate (31.7% -
utilization, 25.2%- expenses), methadone (18.9% - utilization, but contributed to only 
5.1% of entire analgesic-narcotics expenditure), oxycodone (11.4%, 20.3%), 
hydrocodone - acetaminophen (9%, 3.9%), and Eth- Oxydose (7%, 10.1%) were most 
frequently utilized and contributed to majority of expenditures. Fentanyl, whose 
frequency of use was only 5.9% of analgesic-narcotics class, contributed to 21.5% of 
expenditure. 
 
Under therapeutic class laxatives-cathartics, the medications with most frequent 
utilization were senna S (34.9%), senna plus (11.4%), docusate sodium (10.4%), milk of 
magnesia (6.9%) and senna (5.9%). These five medications contributed to approximately 
70% of laxatives-cathartics utilization in the hospices. Under anti-anxiety medication 
class, the medications that were most frequently utilized and contributed to majority of 
expenses included lorazepam (60.3%, 64.6%), alprazolam (29.8%, 15.8%), lorazepam 
intensol (6.3%, 14.1%), diazepam (2%, 1.5%), and busiprone (1%, 0.8%); these 
medications contributed to over 95% of utilization and expenditure of anti-anxiety class. 
Similarly, under SSRIs, the medications were sertraline (40.1%, 44.0%), citlaopram 
(20.6%, 6.9%), paroxetine (17.2%, 19.7%), escitalopram (17%, 22%), and fluoxetine 
(3%, 3%). Under therapeutic class glucocorticoids, the medications contributing to most 
frequent utilization and expenditure were prednisone (67.9%, 18.1%), dexamethasone 
(22.7%, 26.4%), budesonide (3.5%, 38.1%), methylprednisolone (1, 8.1%), and 
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dexamethasone sodium phosphate (1, 0.4%). (Refer Tables 6, 7, 8, 9, 10, 11). 
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Table 6. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class analgesics-narcotics. 
Therapeutic 
Class Drug Name 
Rx 
Count Total Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
ANALGESICS, 
NARCOTICS 
MORPHINE 
SULFATE 3,114 $80,489 31.85% 25.48% 
  OXYCODONE 1,133 $67,893 11.59% 21.49% 
  FENTANYL 548 $64,664 5.61% 20.47% 
  
ETH-
OXYDOSE 659 $30,953 6.74% 9.80% 
  METHADONE 1,941 $17,074 19.85% 5.40% 
ANALGESICS, NARCOTICS 
Total 9,776 $315,926 16.35% 17.00% 
 
 
Table 7. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class laxatives-cathartics. 
Therapeutic 
Class Drug Name 
Rx 
Count Total Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
LAXATIVES 
AND 
CATHARTICS 
SENNA S 1,655  $15,438 34.99% 35.30% 
SENNA PLUS 538  $5,983 11.37% 13.68% 
DOCUSATE 
SODIUM 492  $2,890 10.40% 6.61% 
MILK OF 
MAGNESIA 326  $2,159 6.89% 4.94% 
SENNA 281  $2,252 5.94% 5.15% 
LAXATIVES AND 
CATHARTICS Total 4,730  $43,730 7.91% 2.35% 
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Table 8. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class anti-anxiety drugs. 
Therapeutic 
Class Drug Name 
Rx 
Count 
Total 
Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
ANTI-
ANXIETY 
DRUGS 
LORAZEPAM 2,577  $55,929 59.76% 64.52% 
ALPRAZOLAM 1,284  $13,512 29.78% 15.59% 
LORAZEPAM 
INTENSOL 290  $13,012 6.73% 15.01% 
DIAZEPAM 88  $1,343 2.04% 1.55% 
BUSPIRONE HCL 39  $761 0.90% 0.88% 
ANTI-ANXIETY DRUGS Total 4,312  $86,690 7.21% 4.66% 
 
Table 9. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class SSRIs. 
Therapeutic 
Class Drug Name 
Rx 
Count 
Total 
Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
SELECTIVE 
SEROTONIN 
REUPTAKE 
INHIBITOR 
(SSRIS) 
SERTRALINE  926  $39,337 40.17% 43.95% 
CITALOPRAM  468  $6,070 20.30% 6.78% 
PAROXETINE  411  $18,014 17.83% 20.13% 
ESCITALOPRAM 382  $19,781 16.57% 22.10% 
FLUOXETINE  69  $2,557 2.99% 2.86% 
 (SSRIS) Total 2,305  $89,497 3.86% 4.81% 
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Table 10. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class glucocorticoids. 
Therapeutic 
Class Drug Name 
Rx 
Count Total Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
GLUCOCOR
TICOIDS 
  
  
  
  
PREDNISONE 1,804  $9,321 69.07% 18.68% 
DEXAMETHA
SONE 620  $14,356 23.74% 28.78% 
BUDESONIDE 90  $18,859 3.45% 37.80% 
METHYLPRE
DISOLONE  23  $4,011 0.88% 8.04% 
METHYLPRE
DNISOLONE 14  $458 0.54% 0.92% 
GLUCOCORTICOIDS Total 2,612  $49,888 4.37% 2.68% 
 
Table 11. Medications contributing to most frequent utilization and majority of 
expenditure under therapeutic class antipsychotics, atypical, dopamine & serotonin 
anatagonist. 
Therapeutic 
Class Drug Name 
Rx 
Count
Total 
Cost 
Percentage 
(%) Rx 
Count 
Percentage 
(%) Total 
Cost 
ANTIPSYCHOT
ICS, 
ATYPICAL, 
DOPAMINE & 
SEROTONIN 
ANTAGONIST 
QUETIAPINE 380  $38,780 47.38% 40.39% 
RISPERDAL 303  $34,631 37.78% 36.07% 
ZYPREXA 81  $16,208 10.10% 16.88% 
ZIPRASIDONE 25  $2,431 3.12% 2.53% 
RISPERDAL 
CONSTA 7  $2,411 0.87% 2.51% 
ANTIPSYCHOTICS,ATYPICAL
,DOPAMINE,& SEROTONIN 
ANTAG Total 802  $96,023 1.34% 5.17% 
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Objective 3: To identify five therapeutic drug classes with most frequent utilization 
rates and largest percentage of expenditure in hospice care and analyze five most 
frequently utilized therapeutic classes. 
B) For individual hospice dataset 
Descriptive analyses were run using individual hospice data to identify five therapeutic 
classes and medications that were most frequently utilized and contributing to majority of 
expenditure within each hospice. 
For Hospice 1 
Approximately 236 medications categorized under 105 therapeutic classes were 
utilized in hospice 1. 
Therapeutic drug classes with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
For this objective, claims data for hospice 1 were utilized. Descriptive analysis were 
conducted to identify most utilized therapeutic classes revealed that analgesics-narcotics 
(22.3%), laxatives-cathartics (11.5%), anti-anxiety drugs (7.3%), glucocorticoids (4.9%), 
and loop diuretics (3.5%) were the five most utilized therapeutic drug classes in hospice 
1. These results were found to be consistent with the results obtained using the combined 
dataset. When analyzed to identify therapeutic classes contributing to largest percentage 
of expenditure, analgesics-narcotics, anti-anxiety drugs, selective serotonin reuptake 
inhibitors (SSRIs), beta-adrenergic and glucocorticoid combination and anticonvulsants 
were found as drug classes contributing to majority of expenditure in hospice 1. (Refer 
Table 12 &13) 
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Table 12. Therapeutic classes most frequently utilized in hospice 1. 
Therapeutic Class Rx Count Total Cost Percentage (%) 
ANALGESICS, NARCOTICS 554 $17,747 22.32% 
LAXATIVES AND CATHARTICS 286 $2,579 11.52% 
ANTI-ANXIETY DRUGS 182 $5,089 7.33% 
GLUCOCORTICOIDS 121 $1,762 4.88% 
LOOP DIURETICS 86 $655 3.46% 
Grand Total 1,229 $27,832 49.52% 
Percentage (%) based on Rx Count 
 
Table 13.Therapeutic classes contributing to largest percentage of expenditure in 
hospice 1. 
Therapeutic Class Rx Count Total Cost Percentage (%) 
ANALGESICS,NARCOTICS 554 $17,747 26.26% 
ANTI-ANXIETY DRUGS 182 $5,089 7.53% 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 80 $3,561 5.27% 
BETA-ADRENERGIC AND 
GLUCOCORTICOID 
COMBINATIONS 
13 $3,231 4.78% 
ANTICONVULSANTS 39 $2,932 4.34% 
Grand Total 868 $32,560 48.18% 
 
Percentage (%) based on Total Cost. 
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For Hospice 2 
Therapeutic drug classes with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
Descriptive analyses for calculating frequency of utilization for therapeutic classes and 
those contributing to largest percentage of expenditure were conducted using individual 
data for hospice 2. Most utilized therapeutic classes identified in hospice 2 were 
analgesics-narcotics (20%), anti-anxiety drugs (10.3%), laxatives-cathartics (8.2%), 
glucocorticoids (5%), and SSRIs (4.3%) were the five most utilized therapeutic drug 
classes in hospice 1. These results were found to be consistent with the results obtained 
using the combined dataset. Therapeutic classes contributing to largest percentage of 
expenditure were analgesics-narcotics (20.2%), anti-anxiety drugs (6.6%), selective 
serotonin reuptake inhibitors (SSRIs)(5.8%), anticonvulsants (5.1%) and beta-adrenergic 
and glucocorticoid combination (4.8%). These results were found to be similar to results 
from combined dataset and results of hospice 1. (Refer Tables 14 & 15) 
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Table 14. Therapeutic classes most frequently utilized in hospice 2. 
Therapeutic Class 
Rx 
Count Total Cost Percentage (%)
ANALGESICS,NARCOTICS 1,493 $36,797 20.00% 
ANTI-ANXIETY DRUGS 769 $12,042 10.30% 
LAXATIVES AND CATHARTICS 615 $5,786 8.24% 
GLUCOCORTICOIDS 372 $7,864 4.98% 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 318 $10,512 4.26% 
Grand Total 3,567 $73,001 47.78% 
 
Percentage (%) based on Rx Count. 
 
Table 15. Therapeutic classes contributing to majority of expenditure in hospice 2. 
Therapeutic Class 
Rx 
Count Total Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 1,493 $36,797 20.18% 
ANTI-ANXIETY DRUGS 769 $12,042 6.60% 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 318 $10,512 5.77% 
ANTICONVULSANTS 246 $9,332 5.12% 
BETA-ADRENERGIC AGENTS 146 $8,392 4.60% 
Grand Total 2,972 $77,075 42.27% 
 
Percentage (%) based on Total Cost. 
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For Hospice 3 
Approximately 558 medications under 182 therapeutic classes were utilized in hospice 3. 
Therapeutic drug classes with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
Most utilized therapeutic classes identified in hospice 3 included analgesics-narcotics 
(15.6%), anti-anxiety drugs (5.7%), laxatives-cathartics (9.7%), glucocorticoids (4.4%), 
and gastric acid secretion reducers (4.4%) were the five most utilized therapeutic drug 
classes in hospice 1. These results were found to be consistent with the results obtained 
using the combined dataset. Therapeutic classes contributing to largest percentage of 
expenditure were analgesics-narcotics (16.6%), heparin and related preparations (6.6%), 
antipsychotics, atypical, dopamine, & serotonin antagonist (5.8%), gastric acid secretion 
reducers (4.4%), and antiemetics/antivertigo agents (4.2%). Unlike results from 
combined dataset, therapeutic classes such as heparin and related preparations and 
antiemetics/antivertigo agents contribute to a very large percentage of expenditure in 
hospice 3. (Refer Tables 16 & 17) 
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Table 16. Therapeutic classes most frequently utilized in hospice 3. 
Therapeutic Class 
Rx 
Count Total Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 2,181 $76,044 15.51% 
LAXATIVES AND CATHARTICS 1,338 $11,827 9.52% 
ANTI-ANXIETY DRUGS 798 $18,509 5.68% 
GLUCOCORTICOIDS 615 $8,411 4.37% 
GASTRIC ACID SECRETION REDUCERS 610 $20,036 4.34% 
Grand Total 5,542 $134,826 39.41% 
 
Percentage (%) based on Rx Count. 
 
 
Table 17. Therapeutic classes contributing to majority of expenditure in hospice 3. 
Therapeutic Class Rx Count 
Total 
Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 2,181 $76,044 16.36% 
HEPARIN AND RELATED PREPARATIONS 58 $30,252 6.51% 
ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& 
SEROTONIN ANTAGONIST 292 $26,361 5.67% 
GASTRIC ACID SECRETION REDUCERS 610 $20,036 4.31% 
ANTIEMETIC/ANTIVERTIGO AGENTS 231 $19,136 4.12% 
Grand Total 3,372 $171,829 36.96% 
 
Percentage(%) based on Total Cost 
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For Hospice 4 
Approximately 668 medications were utilized under 198 therapeutic drug classes. 
Therapeutic drug classes with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
Consistent with results obtained from the combined dataset, hospice 1, hospice 2 and 
hospice 3, therapeutic classes most frequently utilized and contributing to largest 
percentage of expenditure in hospice 4 were analgesics, narcotics (16.7%- utilization, 
16.9%-expenditure), anti-anxiety drugs (7.6%, 4.2%), and SSRIs (3.7%, 5%) The classes 
that were most frequently utilized but did not contribute significantly to expenditure in 
hospice 4 included laxatives and cathartics (4.5%), and loop diuretics (4%). Therapeutic 
classes that contributed to majority of expenditure in hospice 4, but were not the most 
frequently utilized ones included antipsychotics, atypical, dopamine & serotonin 
antagonists (5.7%), and beta adrenergic and glucocorticoid combinations (4.2% ). (Table 
18 & 19) 
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Table 18. Therapeutic classes most frequently utilized in hospice 4. 
Therapeutic Class Rx Count Total Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 3,437 $124,290 16.24% 
ANTI-ANXIETY DRUGS 1,573 $30,620 7.43% 
LAXATIVES AND CATHARTICS 932 $10,150 4.40% 
LOOP DIURETICS 820 $6,876 3.87% 
SELECTIVE SEROTONIN REUPTAKE 
INHIBITOR (SSRIS) 765 $37,058 3.61% 
Grand Total 7,527 $208,995 35.57% 
 
Percentage (%) based on Rx Count. 
 
 
Table 19. Therapeutic classes contributing to majority of expenditure in hospice 4. 
Therapeutic Class Rx Count Total Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 3,437 $124,290 16.28% 
ANTIPSYCHOTICS,ATYPICAL,DOPA
MINE,& SEROTONIN ANTAG 289 $41,933 5.49% 
SELECTIVE SEROTONIN REUPTAKE 
INHIBITOR (SSRIS) 765 $37,058 4.85% 
BETA-ADRENERGIC AND 
ANTICHOLINERGIC 
COMBINATIONS 183 $31,117 4.08% 
ANTI-ANXIETY DRUGS 1,573 $30,620 4.01% 
Grand Total 6,247 $265,018 34.71% 
 
Percentage (%) based on Total Cost. 
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For Hospice 5 
Approximately 478 drugs under 168 therapeutic drug classes were utilized in hospice 5. 
Therapeutic drug classes with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
Drug classes that were highly utilized included analgesics, narcotics (14.5%), laxatives-
cathartics (10.7%), anti-anxiety drugs (7%), glucocorticoids (5.2%), and loop diuretics 
(4.3%). These results were almost similar to results obtained earlier from other hospice 
data. Therapeutic classes accounting for majority of expenditure were analgesics, 
narcotics (16%), heparin and related preparations (6.1%), anti-anxiety drugs (5.4%), 
SSRIs (5.2%), and antipsychotics, atypical dopamine, serotonin antagonists (5.1%). 
(Refer Tables 20 & 21) 
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Table 20. Therapeutic classes most frequently utilized in hospice 5. 
Therapeutic Class 
Rx 
Count 
Total 
Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 2,111 $61,049 14.45% 
LAXATIVES AND CATHARTICS 1,559 $13,387 10.67% 
ANTI-ANXIETY DRUGS 990 $20,430 6.78% 
GLUCOCORTICOIDS 759 $16,130 5.19% 
LOOP DIURETICS 631 $3,203 4.32% 
Grand Total 6,050 $114,199 41.40% 
 
Percentage (%) based on Rx Count. 
 
 
Table 21. Therapeutic classes contributing to majority of expenditure in hospice 5. 
Therapeutic Class 
Rx 
Count 
Total 
Cost 
Percentage 
(%) 
ANALGESICS,NARCOTICS 2,111 $61,049 16.04% 
HEPARIN AND RELATED PREPARATIONS 30 $23,110 6.07% 
ANTI-ANXIETY DRUGS 990 $20,430 5.37% 
SELECTIVE SEROTONIN REUPTAKE 
INHIBITOR (SSRIS) 609 $19,864 5.22% 
ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& 
SEROTONIN ANTAGONIST 136 $19,443 5.11% 
Grand Total 3,876 $143,895 37.81% 
 
Percentage (%) based on Total Cost. 
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Objective 4: To identify ten medications with most frequent utilization rates and 
largest percentage of expenditure in hospice care. 
A) For Combined Dataset 
Ten medications with most frequent utilization rates and largest percentage of 
expenditure in hospice care. 
Medications whose frequency of use accounted for high utilization as well as 
expense included morphine sulfate (5.2% - utilization, 4.3% - expenditure) and 
lorazepam (4.4%, 3.0 %), while medications such as furosemide (4%, 0.6%), methadone 
(3.25%, 0.9%), and prednisone (3.0%, 0.5%) contributed highly to utilization, but were 
not a significant contributor to expenditure. There were certain medications such as 
enoxaparin injections whose frequency of utilization was low (0.01%), but contributed to 
3.1% of total medication expenditure. Likewise, fentanyl and oxycodone contributed to 
3.5% and 3.7%, respectively to the total medication expenditure, but their frequency of 
utilization was very low, only 0.9% and 1.9%, respectively (Refer Tables 22 and 23).   
 
The listed 10 medications (Table 22) were the most significant contributors to 
utilization. They accounted for 31% of entire medication utilization in the hospices. Table 
23 lists the top 10 medications contributing significantly to expenditures. Out of the 
1,020 medications, the listed medications contributed to about 27.5% of total 
expenditure. 
 
 
 76 
 
Table 22. Ten medications sorted by prescription (Rx) count (combined dataset) 
Drug Name Rx Count Total Cost  Percentage % 
MORPHINE SULFATE 3,114 $80,489 5.21% 
LORAZEPAM 2,606 $56,552 4.36% 
FUROSEMIDE 2,148 $10,949 3.59% 
METHADONE  1,941 $17,074 3.25% 
PREDNISONE 1,804 $9,321 3.02% 
SENNA S 1,655 $15,438 2.77% 
HALOPERIDOL 1,466 $21,225 2.45% 
ALPRAZOLAM 1,284 $13,512 2.15% 
MIRTAZAPINE 1,171 $38,026 1.96% 
OXYCODONE HCL 1,133 $67,893 1.90% 
Grand Total 18,322 $330,481 30.65% 
Percentage (%) based on  total Rx Count. 
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Table 23. Ten medications sorted by total costs. (Combined dataset) 
 
Drug Name Rx Count Total Cost Percentage % 
MORPHINE SULFATE 3,114 $80,489 4.33% 
OXYCODONE  1,133 $67,893 3.65% 
FENTANYL 548 $64,664 3.48% 
LORAZEPAM 2,606 $56,552 3.04% 
ENOXAPARIN INJECTIONS 63 $56,511 3.04% 
SERTRALINE  926 $39,337 2.12% 
QUETIAPINE 380 $38,780 2.09% 
MIRTAZAPINE 1,171 $38,026 2.05% 
RISPERDAL 303 $34,631 1.86% 
OXYCODONE 659 $30,953 1.67% 
Grand Total 10,903 $507,836 27.32% 
 
%  percentage based on  total Cost. 
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Objective 4: To identify ten medications with most frequent utilization rates and 
largest percentage of expenditure in hospice care. 
B) For individual hospice dataset 
Descriptive analyses were run using individual hospice data to identify five therapeutic 
classes and medications that were most frequently utilized and contributing to majority of 
expenditure within each hospice 
For Hospice 1 
 Medications with most frequent utilization rates and largest percentage of expenditure 
in hospice care. 
Medications that were most frequently utilized and contributed to largest percentage of 
expenditure in hospice 1 included methadone (7.6%-utilization, 2.8%-expenditure), 
morphine sulfate (7.2%, 7%), lorazepam (3.4%, 3.7%), and oxycodone (3.1%, 10%). 
Furosemide (3.1%) was also found to be frequently utilized, but contributed to only about 
0.6% of expenditure; while fluticasone propionate (4.8%) contributed to a large 
percentage of expenditure. (Refer Tables 24 & 25) 
 
 These listed medications in tables 24 & 25 alone contributed to 27.5% of 
utilization & 25% of total medication expenditure in hospice 1. 
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Table 24. Medications most frequently utilized in hospice 1. 
 
Drug Name Rx Count Total Cost Percentage (%) 
METHADONE  189 $1,873 7.61% 
MORPHINE SULFATE 179 $4,737 7.21% 
LORAZEPAM 84 $2,500 3.38% 
FUROSEMIDE 78 $393 3.14% 
OXYCODONE  76 $6,784 3.06% 
Grand Total 682 $16,762 27.48% 
 
Percentage (%) based on Rx Count 
 
Table 25. Medications contributing to majority of expenditure in hospice 1. 
Drug Name Rx Count Total Cost Percentage (%) 
OXYCODONE  76 $6,784 10.04% 
MORPHINE SULFATE 179 $4,737 7.01% 
FLUTICASONE PROPIONATE 13 $3,231 4.78% 
LORAZEPAM 84 $2,500 3.70% 
METHADONE 189 $1,873 2.77% 
Grand Total 541 $19,126 28.30% 
Percentage (%) based on Total Cost. 
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For Hospice 2 
Medications with most frequent utilization rates and largest percentage of expenditure 
in hospice care. 
Medications, whose frequency of use contributed to majority of expenditure in hospice 2 
included lorazepam (9.1%-utilization, 5.9%-expenditure) and morphine sulphate (8.9%, 
6.4%). Other medications most frequently utilized included senna S (4%), prednisone 
(3.3%), haloperidol (2.9%); and medications that contributed to majority of expenditure 
included fentanyl (5.9%), oxycodone (2.8%) and sertraline (2.8%). (Refer Tables 26 & 
27). 
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Table 26. Medications most frequently utilized in hospice 2. 
Drug Name Rx Count Total Cost Percentage (%) 
LORAZEPAM 681 $10,763 9.12% 
MORPHINE SULFATE 663 $11,742 8.88% 
SENNA S 301 $2,611 4.03% 
PREDNISONE 250 $1,179 3.35% 
HALOPERIDOL 213 $2,781 2.85% 
Grand Total 2,108 $29,076 28.24% 
 
Percentage (%) based on Rx Count. 
 
 
Table 27. Medications contributing to majority of expenditures in hospice 2. 
 
 
Drug Name Rx Count Total Cost Percentage (%) 
MORPHINE SULFATE 663 $11,742 6.44% 
FENTANYL 89 $10,777 5.91% 
LORAZEPAM 681 $10,763 5.90% 
OXYCODONE 136 $5,060 2.77% 
SERTRALINE  155 $5,052 2.77% 
Grand Total 1,724 $43,393 23.80% 
 
Percentage (%) based on Total Cost. 
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For Hospice 3 
Medications with most frequent utilization rates and largest percentage of expenditure 
in hospice care. 
Morphine sulphate was most frequently utilized and contributed to significant 
expenditure. Medications that were highly utilized in hospice 3 included furosemide 
(3.9%), lorazepam (3.8%), senna S (3.1%), and methadone HCl (2.6%). Medications that 
accounted to large expenditures included enoxaparin injections (6.5%), fentanyl (5.5%), 
risperdal (2.9%), and oxycodone (2.8%). (Refer Tables 28 & 29) 
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Table 28. Medications most frequently utilized in hospice 3. 
Drug Name Rx Count Total Cost Percentage (%) 
MORPHINE SULFATE 813 $21,981 5.78% 
FUROSEMIDE 541 $2,644 3.85% 
LORAZEPAM 537 $10,328 3.82% 
SENNA S 434 $3,878 3.09% 
METHADONE  360 $2,929 2.56% 
Grand Total 2,685 $41,760 19.10% 
 
Percentage (%) based on Rx Count. 
 
 
Table 29 . Medications contributing to majority of expenditure in hospice 3. 
Drug Name Rx Count Total Cost Percentage (%) 
ENOXAPARIN INJECTIONS 28 $29,889 6.43% 
FENTANYL 228 $24,962 5.37% 
MORPHINE SULFATE 813 $21,981 4.73% 
RISPERDAL 117 $13,420 2.89% 
OXYCODONE  225 $12,939 2.78% 
Grand Total 1,411 $103,191 22.20% 
Percentage (%) based on Total Cost. 
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For Hospice 4 
Medications with most frequent utilization rates and largest percentage of expenditure 
in hospice care. 
Morphine sulphate was the most utilized medication (4.8%) that contributed to the largest 
percentage of expenditure (4.1%) in hospice 4; while lorazepam contributed to 2.5% of 
expenditures with 3.4% of utilization rate. Other most utilized medications were 
alprazolam (3.7%), furosemide (3.6%), and methadone (3.3%); and medications with 
largest percentage of expenditure included fentanyl (3.2%), oxycodone (3%), sertraline 
HCl (2.4%). (Refer tables 30 & 31) 
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Table 30. Medications most frequently utilized in hospice 4. 
 
Drug Name Rx Count Total Cost Percentage (%) 
MORPHINE SULFATE 990 $29,795 4.68% 
ALPRAZOLAM 760 $8,131 3.59% 
FUROSEMIDE 745 $4,042 3.52% 
LORAZEPAM 693 $18,040 3.27% 
METHADONE  674 $6,973 3.18% 
Grand Total 3,862 $66,981 18.25% 
Percentage (%) based on Rx Count. 
 
 
Table 31. Medications contributing to majority of expenditures in hospice 4. 
 
Drug Name Rx Count Total Cost Percentage (%) 
MORPHINE SULFATE 990 $29,795 3.90% 
FENTANYL 172 $23,687 3.10% 
OXYCODONE  262 $22,073 2.89% 
LORAZEPAM 693 $18,040 2.36% 
SERTRALINE  351 $17,586 2.30% 
Grand Total 3,025 $140,336 18.38% 
Percentage (%) based on Total Cost. 
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For Hospice 5 
Medications with most frequent utilization rates and largest percentage of expenditure 
in hospice care. 
Lorazepam was the medication whose frequency of use contributed to majority of 
expenditure (4.2%-utilization, 3.9%-expenditure). Senna S (5%), furosemide (4.3%), 
prednisone (3.9%), and methadone (3.7%) were the medications that were most 
frequently utilized in hospice 5. Medications that contributed to largest percentage of 
expenditure included oxycodone (6%), enoxaparin injections (5.7%), mirtazapine (3%), 
morphine sulphate (3.2%). (Refer Tables 32 & 33) 
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Table 32. Medications most frequently utilized in hospice 5. 
Drug Name Rx Count Total Cost Percentage (%) 
SENNA S 723 $5,943 4.95% 
FUROSEMIDE 630 $3,171 4.31% 
LORAZEPAM 611 $14,921 4.18% 
PREDNISONE 564 $2,868 3.86% 
METHADONE  546 $4,055 3.74% 
Grand Total 3,074 $30,958 21.04% 
 
Percentage (%) based on Rx Count. 
 
Table 33. Medications contributing to majority of expenditures in hospice 5. 
Drug Name Rx Count Total Cost Percentage (%) 
OXYCODONE  462 $22,967 6.04% 
ENOXAPARIN 
INJECTIONS 29 $21,569 5.67% 
LORAZEPAM 611 $14,921 3.92% 
MORPHINE SULFATE 469 $12,235 3.22% 
MIRTAZAPINE 373 $11,231 2.95% 
Grand Total 1,944 $82,923 21.79% 
 
Percentage (%) based on Total Cost. 
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Finally, analyses were conducted to find percentage of therapeutic class and 
medication utilization by each hospice. Descriptive analysis suggested that analgesics-
narcotics was most frequently utilized by hospice 4 (35.2% of the overall analgesic-
narcotic utilization by all five hospices), followed by hospice 3 (22.3%) and hospice 
5(21.6%). Therapeutic class laxatives-cathartics was most frequently utilized by hospice 
5 (33%), hospice 3 (28.3%), and by hospice 4 (19.7%); while anti-anxiety drugs were 
highly utilized by hospice 4 (36.5%), hospice 5 (23%), hospice3 (18.5%) and hospice 2 
(17.2%). Glucocorticoids were found to be utilized most frequently in hospice 5 (29.1%), 
hospice 4 (28.5%) and hospice 3 (27.5%). Hospice 4 (33.2%, 36.3%, 38.7%, 34.5%), 
followed by hospice 5 (26.4%, 27.9%, 27.1%, 31.8%) and hospice 3 (23.1%, 25.2%, 
16.2%, 19.6%) were found to most frequently utilize therapeutic classes such as SSRIs, 
loop diuretics, antipsychotics - dopamine antagonists - butyrophenones, and alpha-2 
receptor antagonist antidepressants, respectively. Gastric acid secretion reducers were 
most frequently utilized by hospice 3, followed hospice 5 and hospice 4. Anticonvulsants 
were frequently utilized by hospice 4, hospice 3 and hospice 5. (Refer Table 34-A) 
 
For medication utilization, hospice 5 utilized majority of oxycodone (40.8%). 
Hospice 4 had the highest frequency of utilization for morphine sulphate (31.8%), 
methadone HCl (34.7%), alprazolam (59.19%), haloperidol (40.65%), methadone 
(34.72%), and mirtazapine (34.5%). (Refer Table 34-B)
  
Table 34-A. Therapeutic class utilization by Ohio hospices 
 Hospice 1 Hospice 2 Hospice 3 Hospice 4 Hospice 5  
Therapeutic Class Rx Count  (%) Rx Count  (%) 
Rx 
Count  (%) 
Rx 
Count  (%) 
Rx 
Count  (%) Total 
ANALGESICS, NARCOTICS 554 5.67% 1,493 15.27% 2,181 22.31% 3,437 35.16% 2,111 21.59% 9,776 
LAXATIVES AND CATHARTICS 286 6.05% 615 13.00% 1,338 28.29% 932 19.70% 1,559 32.96% 4,730 
ANTI-ANXIETY DRUGS 182 4.22% 769 17.83% 798 18.51% 1,573 36.48% 990 22.96% 4,312 
GLUCOCORTICOIDS 121 4.63% 372 14.24% 615 23.55% 745 28.52% 759 29.06% 2,612 
SELECTIVE SEROTONIN 
REUPTAKE INHIBITOR (SSRIS) 80 3.47% 318 13.80% 533 23.12% 765 33.19% 609 26.42% 2,305 
LOOP DIURETICS 86 3.81% 154 6.81% 569 25.18% 820 36.28% 631 27.92% 2,260 
GASTRIC ACID SECRETION 
REDUCERS 48 2.35% 251 12.30% 610 29.90% 551 27.01% 580 28.43% 2,040 
ANTIPSYCHOTICS,DOPAMINE 
ANTAGONISTS,BUTYROPHENO
NES 
71 4.41% 219 13.60% 261 16.21% 623 38.70% 436 27.08% 1,610 
ANTICONVULSANTS 39 2.88% 246 18.17% 319 23.56% 472 34.86% 278 20.53% 1,354 
ALPHA-2 RECEPTOR 
ANTAGONIST 
ANTIDEPRESSANTS 
29 2.47% 136 11.60% 230 19.62% 404 34.47% 373 31.83% 1,172 
Grand Total 1,496 4.65% 4,573 14.21% 7,454 23.17% 10,322 32.08% 8,326 25.88% 32,171 
Percentage (%) based on Rx Count. 
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Table 34-B. Therapeutic class utilization by Ohio hospices 
 Hospice 1 Hospice 2 Hospice 3 Hospice 4 Hospice 5  
Therapeutic Class Rx Count  (%) 
Rx 
Count  (%) 
Rx 
Count  (%) 
Rx 
Count  (%) 
Rx 
Count  (%) Total 
MORPHINE SULFATE 179 5.75% 663 21.29% 813 26.11% 990 31.79% 469 15.06% 3,114 
LORAZEPAM 84 3.22% 681 26.13% 537 20.61% 693 26.59% 611 23.45% 2,606 
FUROSEMIDE 78 3.63% 154 7.17% 541 25.19% 745 34.68% 630 29.33% 2,148 
METHADONE  
189 9.74% 172 8.86% 360 18.55% 674 34.72% 546 28.13% 1,941 
PREDNISONE 71 3.94% 250 13.86% 356 19.73% 563 31.21% 564 31.26% 1,804 
SENNA S 17 1.03% 301 18.19% 434 26.22% 180 10.88% 723 43.69% 1,655 
HALOPERIDOL 54 3.68% 213 14.53% 233 15.89% 596 40.65% 370 25.24% 1,466 
ALPRAZOLAM 49 3.82% 69 5.37% 82 6.39% 760 59.19% 324 25.23% 1,284 
MIRTAZAPINE 29 2.48% 135 11.53% 230 19.64% 404 34.50% 373 31.85% 1,171 
OXYCODONE  76 6.71% 108 9.53% 225 19.86% 262 23.12% 462 40.78% 1,133 
Grand Total 826 4.51% 2,746 14.99% 3,811 20.80% 5,867 32.02% 5,072 27.68% 18,322 
Percentage (%) based on Rx Count.
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Further, the PPPD medication costs of study hospices were compared with 
nationwide hospices for benchmarking purposes. The PPPD medication costs for 
nationwide hospices were found from Milliman study(1998) and PoPCRN study(2001) 
(Refer Table 36). The costs from these studies were inflated to year 2007 costs for 
appropriate comparison. For inflating the costs from earlier years, medical cost inflation 
rate from year 1998 -2007 were obtained from United States Bureau of Labor Statistics. A 
cumulative inflation rate for these years was computed, which was found to be 42.3% 
(Refer Table 35). The 1998 and 2001 year costs were inflated to 2007 year costs using the 
following formula: 
∑ Inflation Rate = (P0 – P-1)/ P-1*100 
where; 
 P0 = Price/Cost of goods in present year; 
P-1 = Price/Cost of goods in the earlier year; 
∑ Inflation Rate = Cumulative inflation rate. 
 
For calculating the average PPPD medication costs in study hospices, total costs 
for medications per day was divided by number of patients. It was found that certain 
medications such as enoxaparin acted as outliers, whose utilization was minimal, but 
contributed to over 3% of total medication expenditues. Such outliers were excluded in 
the calculation of PPPD. On comparing these inflated costs to the costs from study 
hospices, it was found that costs of PPPD medication cost ($10.72 – with the exclusion of 
outlier) in study hospices was significantly lower than inflated PPPD medication costs of 
Milliman study ($22.1) and PoPCRN study ($14.7) (Refer Table 35). 
 92 
 
Table 35. Medical cost inflation rates. Source: U.S Beareau of Labor Statistics. 
Year 
Medical Cost 
Inflation Rate 
Cumulative Medical Cost Inflation 
Rate 
1998 3.20% 3.20% 
1999 3.50% 6.70% 
2000 4.10% 10.80% 
2001 4.60% 15.40% 
2002 4.70% 20.10% 
2003 4.00% 24.10% 
2004 4.80% 28.50% 
2005 4.40% 32.70% 
2006 4.20% 36.70% 
2007 4.80% 42.30% 
1998-2007  42.30% 
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Table 36. Comparison of medication costs (PPPD) 
 Milliman Study 
PoPCRN 
Study 
Study Hospices 
Original Year 1998 2001 2007 
PPPD for Original Years $15.72 $11.47 $10.72 
Inflated Costs to Year 2007 $22.10 $14.37 $10.72 
 
PPPD=Per Patient Per Day cost; PoPCRN=The Population-based Palliative Care Research Network. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
This chapter discusses the findings of this study, draws conclusions, presents 
implications, and provides limitations of the study. 
 
This study is an exploratory study and a part of the study analyzed the patient and 
hospice related characteristics of the study hospices and compared it with nationwide 
hospices using 2007 NHPCO data. The primary focus of this study was to analyze the 
medication costs and utilization in hospice care, for which PBM claims data for year 
2007 were utilized. It was observed that pharmacy cost is a major component of total 
costs of hospice care. Therefore, the study identified some key elements (therapeutic 
classes and medications) contributing to significant medication costs produced by hospice 
care. 
 
An analysis of reports provided by the five study hospices found that average 
number of admissions for the study hospices combined was 627 patients for year 2007. 
The average daily census (136 patients) and total patient days (51,350 days) in these five 
hospices were 1.5 times higher as compared to that of NHPCO data (90 patients and 
31,300 days, respectively). This implies that study hospices were relatively larger sized 
hospices. It was also observed that there was equal number of male and female 
admissions in 2007; comparing with nationwide hospices using NHPCO data, the number 
of male admissions was found to be higher. Similar to NHPCO data (55.1%), number of 
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patients with non-cancer diagnosis (58.5%) was higher than those with cancer in these 
hospices. 
 
Some variables that were analyzed from reports provided by study hospices 
included, but not compared with NHPCO data were net operating revenues, physician, 
nursing salary, bereavement costs, DME costs and inpatient unit costs. Net operating 
revenues of the Ohio hospices ranged from a minimum of $500,000/ hospice to $13.8 
million/ hospice. The difference in net operating revenues (NOR) was very high, 
suggesting a possibility that a few hospices were run on a smaller scale as compared to 
other hospices, where the NOR were in millions. Four out of five hospices had inpatient 
units and the inpatient unit (IPU) operating costs varied from $700,000/ hospice to $1.7 
million/ hospice. Average physician salary was lower than average nursing salary because 
these salaries reflect on the total expenditures made by the hospice on physician salary 
and nursing salary. Hospice interdisciplinary team typically consists of one physician; but 
approximately 10 to 20 nurses, which justifies a higher proportion of expenditure on 
nursing salaries. 
 
Approximately 1,020 different drugs under 246 therapeutic classes were utilized 
in the five hospices. The most frequently utilized therapeutic class of drugs, based on 
prescription drug volume included analgesic-narcotics (15.6%) followed by laxatives-
cathartics (7.5%), and anti-anxiety drugs (7%). These results are self-explanatory as 
mentioned in Chapter 1, because hospice care is primarily focused on pain and symptom 
management, and in making the patient feel comfortable. When analyzing therapeutic 
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classes contributing to the majority of drug expenditures, it was found that these included 
analgesics-narcotics (16.5%), SSRIs (4.7%), and anti-anxiety drugs (4.5%). Since the 
utilization of analgesics, narcotics and anti-anxiety drugs is very high, the medication 
expenditure in these classes is also very high. However, laxatives-cathartics, which 
followed second for utilization was not observed as a major expenditure contributor. This 
may be because laxatives-cathartics are relatively inexpensive drugs. SSRIs were found 
to be the major contributor to expenditures. To explain this, further analyses for analyzing 
each highly utilized therapeutic classes were conducted. 
 
Upon analyzing, analgesics-narcotics, it was observed that morphine sulfate and 
methadone were the two most frequently utilized medications [morphine (31.7% - 
utilization, 25.2% - expenditure), methadone (18.9%, 5.1%) and oxycodone (11.4%, 
20.3%)]. Fentanyl contributed to 22% of analgesic-narcotic expenditure; however, its 
utilization was only 5.6%. Methadone is very frequently utilized; however the percentage 
of expenditure it contributes to total analgesics-narcotics is very low. Such cost-effective 
medications should be highly recommended for utilization. Under laxatives-cathartics, 
the most frequently utilized medications included senna, docusate sodium, senna S. These 
medications have very low prices, hence, laxatives-cathartics are not found as a major 
contributor to expenditures. However,  for therapeutic class SSRI, medications that 
contributed to major utilization as well as high expenditure rates included sertaline 
(40.1% utilization, 44% expenditure), citalopram (20.6%, 6.9%), paroxetine (17.2%, 
19.7%), and escitalopram (17%, 22%). Sertraline and escitalopram are expensive 
medications contributing to major expenditure to the hospices. 
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Medications whose frequency of use accounted for high expense included 
morphine sulfate (5.3% - utilization, 4.4% - expenditure), lorazepam (4.4%, 3.1%.), 
furosemide (4%, 0.6%), methadone (3%, 0.9%), and prednisone (3.1%, 0.5%). These 
medications fall under the highly utilized therapeutic classes. They explain the most 
frequent utilization of the therapeutic classes. Furthermore, medications such as 
Enoxaparin injections whose frequency of utilization was low (0.01%), contributed to 
3.1% of total medication expenditure. Likewise, fentanyl and oxycodone contributed to 
3.5% and 3.7%, respectively to the total medication expenditure, but their frequency of 
utilization was only 0.9% and 1.9%, respectively. Such medications that do not prove to 
be cost-effective, should be reviewed by pharmacists and their utilization should be 
minimized. 
 
Furthermore, medications whose frequency of use accounted for high expense 
were analyzed within the identified therapeutic classes. For therapeutic class analgesic-
narcotics, medications whose frequency of use contributed to major expenses were 
morphine (31.7% - utilization, 25.2% - expenditure), methadone (18.9%, 5.1%) and 
oxycodone (11.4%, 20.3%). Fentanyl contributed to 22% of analgesic-narcotic 
expenditure, however, its utilization was only 5.6%. Medications under therapeutic class 
laxatives & cathartics included senna (36.7% of expense), senna plus (11.4%) and 
docusate sodium (9.5%). Similarly, medications for treatment of anxiety, which 
contributed to approximately 90% of expenses, were lorazepam (60.2% - utilization, 
64.2% - expenditure), alprazolam (29.8%, 15.8%), and lorazepam intensol (6.3%, 
14.1%). 
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Overall, comparing the medication PPPD costs of study hospice with nationwide 
hospices, it was found that costs for medications at study hospices were low. This result 
could be attributed to the fact that the study hospices employ pharmacists for medication 
review. Hence, the utilization of cost-effective medications such as methadone and 
citalopram is high, while utilization of costly agents such as fentanyl, oxycodone and 
enoxaparin injections is low.  
 
CONCLUSION OF THE STUDY 
 
Health expenditures in the United States neared $2.3 trillion in 2007, over 
ten times the $256 billion spent in 1980. 66 Prescription drugs have been the fastest-
growing component of health care costs. In 2007, prescription drug expenditures grew to 
$236 billion, which is over twenty times of $12 billion expenditures in 1980s 66 
 
Prescription drug costs are rising because of the availability of more expensive 
and new drugs (accounting for 38% of the cost increase), greater overall utilization of 
prescription drugs (44%), and drug price inflation (18%).4 The increase is further fueled 
by the aging of the baby boom generation, the largest U.S. population cohort, that are 
beginning to suffer the chronic illnesses of old age. Additionally, many drug 
manufacturers use direct-to-consumer advertising to stimulate demand for new and more 
expensive drug products. With the advent of newer drugs every year and the 
pharmaceutical world now stepping into the very expensive, specialty drugs, the need for 
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research to evaluate cost-effective medications has become imperative. It has become 
necessary to find and employ new interventions to control the costs of such products. 
These high costs prove to be burdensome on patients, and the society, as a whole, and 
essential steps should be taken to lever such situation. 
 
This study suggests that pharmacists led interventions are a useful way to lower 
the costs and recommend cost-effective medications for patients. Pharmacists are an 
important link to physician/patient relationship. The present study aimed at identifying 
medications and therapeutic classes that contributed to majority of the expenditure and 
utilization in hospices that utilize clinical pharmacists for drug utilization review. It was 
found the pppd costs in the study hospices were lower than pppd costs for hospices 
nationally. This proves the fact that pharmacist led interventions such as medication 
review has the potential to bring cost savings.  
 
In this study, the five study hospices employ preferred drugs recommended by 
pharmacists following a medication review to identify potential drug related problems 
(DRPs) and encourage cost-effective drug utilization. As a result of these interventions, 
the utilization of medications such as fentanyl patches, enoxaparin injections and 
oxycodone is low. Use of medications such as methadone, alprazolam, prednisone, 
citalopram should be recommended. 
 
The overall costs for hospice care to Medicare, other third party payers and 
patients may be less as compared to the costs incurred by conventional care, but the most 
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important element to hospice care, the cost for medications (8% - 40% of net operating 
revenues) still holds opportunity to be minimized. Especially, with the introduction of 
Patient Protection plan (2010) and ACA, and the new hospice payment rules, phase-out 
of Budget Neutrality Adjustment Factor (BNAF) will be implemented, leading to a 
reduction in market basket update. Due to this, it has been estimated that median 
Medicare profit margin for the hospice industry could decrease from 4% in 2008 to -11% 
by 2019. This could severely affect hospices that serve rural patients, leading to an 
overall negative profit margin in 66% of hospices by 2019. This will result to tremendous 
difficulty in operation of hospice care. Therefore, hospice care needs to discover every 
opportunity to strategize the reduction in costs incurring in serving the patients. 67 
 
Pharmacists specializing in hospice and palliative care are able to recommend 
appropriate and effective drug therapy as an alternative to high cost, high risk 
medications and produce cost-savings; also identify DRPs which have the potential to 
influence better patient outcomes. Hospices throughout the nation should consider putting 
into effect such interventions made by pharmacists and place emphasis on the utilization 
of cost effective drugs that can be used among terminally ill patients to provide a high 
level of quality care with fiscal responsibility. 
 
PBMs are a very important link between the pharmaceutical manufacturers, 
suppliers and the institutions providing health care services. On the basis of drug 
utilization research (DUR) and cost-effectiveness research, PBMs are able to make 
changes to the drug formulary. They help in providing patients and the institutions such 
 101 
 
as hospices with appropriate medications-the foundation for selection of medications 
being medication review by pharmacists. Thus, assisting hospices in achieving cost 
savings, along with a high quality of clinical effectiveness.  
 
IMPLICATIONS OF THE STUDY 
 
This study is important for 2 main reasons: this study provides information on 
cost savings produced by pharmacist-led interventions such as medication review in 
hospice care; and analyzes all the important medications utilized in hospice care. There is 
a dearth in literature regarding information on medications costs and utilization in 
hospice care. This study will demonstrate as a benchmark for nationwide hospices for 
information on medications used in hospice care. 
 
LIMITATIONS OF THE STUDY 
 
The study has some potential limitations. Firstly, the inherent limitations of a 
retrospective database are applicable to this study as well. Retrospective databases are 
often questioned in terms of validity because of possible issues with misclassification 
bias, selection bias, confounding factors, sponsorship, data quality, and privacy. Secondly, 
the claims data have their own limitations for conducting the study. Claims data are also 
questioned since they don’t provide enough of the information researchers need to 
develop and improve evidence-based guidelines. Furthermore, literature suggests that 
bias promoted by the insurance industry by encouraging and supporting the adage "less is 
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more" may make claim’s data unreliable. 
 
Based on the nature of the data available, only exploratory and descriptive type of 
research designs were used in the study. Patient-level claims data would have been ideal 
to research further into demographic factors affecting or driving the medication costs at 
hospice care. Furthermore, data for only five hospices were analyzed, making it difficult 
to generalize the results to an entire population. 
 
For comparison of medication costs, previous published data from studies have 
been utilized to give an overall idea for the cost savings produced pharmacist led 
interventions, assuming that all hospices that participated in previous published studies, 
were a mix of hospices that employ pharmacists led intervention and those that do not 
employ pharmacist led interventions. The results would prove more appropriate and 
robust, if PBM claims data for hospices that do not use pharmacists interventions were 
utilized to compare with our study hospices that employ pharmacist’s interventions. 
 
In this study, reports provided by hospices have been utilized as resource to 
understand hospice and patient related characteristics. Hence, robust statistical analyses 
were not conducted. From, statistical point of view, analysis such as regression and power 
analysis can be conducted to find the relationship between medication utilization and 
patient/hospice-related variables. Results show that length of service (LOS) at hospice 
care is highly skewed, to further study the LOS and the factors that affect LOS, survival 
analysis would be very beneficial. 
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